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Abstract
CHARGE syndrome describes a combination of severe develop-
mental defects including, among other things, a delayed or retarded
mental development, sometimes combined with a variety of psycho-
logical symptoms. Especially the molecular mechanisms behind this
brain phenotype is little understood, and cannot be treated effectively
up to now.
This syndrome is caused by a heterozygous mutation in the Chro-
modomain helicase protein 7 (chd7) gene, which encodes an epigeneti-
cally active protein (CHD7) mediating nucleosome sliding, and asso-
ciated with open and active chromatin (H3K27ac, Feng et al., 2017).
Another epigenetically active protein fulfilling an opposite task is
EZH2 (the catalytic part of the polycomb repressive complex 2 (PRC2))
which silences gene expression by methylating histon 3 lysin 27.
Both EZH2 and CHD7 are expressed in overlapping brain regions,
and a knock-out of the respective protein has opposing effects on
neuronal branching (Feng et al., 2013 and Liu, Y.). With these hints it
was hypothesized that EZH2 might counteract CHD7 deficiency and
could be beneficial for the CHARGE condition.
In the frame of this thesis I was able to generate and analyze
a CHARGE mouse (CMVCre;CHD7+/fl) that displayed a variety
of CHARGE related symptoms. Heterozygous chd7 mutant mice
had a reduced body weight, were significantly more active, devel-
oped sever eye malformations with narrowed palpebral fissures,
significantly smaller eye diameter, a thinner retina and inner nuclear
layer, and partially completely dysfunctional eyes. Furthermore, the
cerebellum of CHARGE mice showed a missing anterior lobe, and
a disorganized purkinje cell layer with less primary branches. Also
CHARGE mice have less neurogenesis ind the hippocampus.
Following the main hypothesis a genetic rescue
(CMVCre;CHD7+/fl;EZH2+/fl) could restore; body and brain
size, the strong eye malformations observed under CHARGE
conditions, the amount of neural stem cells in the dentate gyrus,
and the cerebella purkinje cell layer. Moreover, an RNA sequenc-
ing of the cerebellum tissue revealed that the gene expression of
many genes in the double knock-out was indeed rescued. Further-
more, a homozygous inducible double knock-out of chd7 and ezh2
(NesCreERT2;CHD7fl/fl;EZH2fl/fl) rescued the neural stem cell
pool in comparison to a chd7 single knock-out.
Finally, these findings encourage me to use a very potent EZH2
inhibitor to treat neural stem cells in vitro and in vivo, thus attempting
a novel CHD7 deficient treatment.
Zusammenfassung
Das CHARGE Syndrom besteht aus einer Kombination schwerer En-
twicklungsdefekte. Insbesondere die molekularen Hintergründe des
Gehirns Phänotyps die in teilweise schweren psychischen Stˆrungen
und sogar geistigen Behinderungen resultieren können, sind wenig
untersucht und können derzeit nicht behandelt werden. Diese
Krankheit wird von einer heterozygoten Mutation im Chromatin DNA
Helicase 7 (chd7) Gen verursacht, das ein Protein kodiert das Nukleo-
somen verschiebt und mit offenem, aktivem Chromatin assoziiert ist
(H3K27ac) (Feng et al., 2017).
Eine funktional gegenteilige Chromatinmarkierung, nämlich die
einfach- zweifach und dreifach Methylierung von Histon 3 Lysin
27 wird von EZH2 umgesetzt, welches der katalytische Teil des
polycomb repressive complex 2 (PRC2) ist. CHD7 und EZH2 werden in
ähnlichen Hirnregionen exprimiert und es konnte gezeigt werden,
dass ein knock-out des jeweiligen Proteins gegenteilige Effekte auf
die Ausbildung neuronaler Dendriten hat (Feng et al., 2013 and Li,
Y). All diese Hinweise führten zu der Hypothese, dass EZH2 in der
Lage sein könnte einen Teil des CHD7 Phänotyps auszugleichen.
Im Rahmen dieser Arbeit konnte ich eine CHARGE Maus
(CMVCre;CHD7+/fl) kreuzen und analysieren, die viele CHARGE-
ähnliche Symptome zeigte. Diese heterozygoten chd7 knock-out
Mäuse waren signifikant kleiner und aktiver als die Kontrolltiere,
sie zeigten schwerwiegende Fehlentwicklungen der Augen, die ein
geringeren Augendurchmesser, einen dünnere innere Körnerschicht
der Retina, sowie komplette Fehlbildungen der Augen ohne Pupille
und mit geschlossenen Augenlidern beinhalten. Weiterhin zeigte das
Kleinhirn einen fehlenden anterioren Lobus und eine unorganisierte
Purkinjezellschicht mit reduzierter Dendritenbildung. Weiterhin
konnte ich in CHARGE Mäusen signifikant weniger BrdU und Nestin
positive Stammzellen im Gyrus Dentatus nachweisen.
Unserer Haupthypothese folgend, generierte ich einen genetischen
Rescue der CHARGE Maus (CMVCre;CHD7+/fl;EZH2+/fl), diese
Mäuse hatten ein normales Gewicht, normal entwickelte Augen,
ein unauffälliges Kleinhirn mit intakter Purkinjezellschicht und eine
normale Menge and BrdU und Nestin positiven Stammzellen im
Gyrus Dentatus. Darüber hinaus zeigte eine RNA Sequenzierung
des Kleinhirngewebes, dass die Expression vieler Gene im Doppel-
Knockout normalisiert waren. Außerdem konnte ein homozygoter
Knockout von chd7 und ezh2 (NesCreERT2;CHD7fl/fl; EZH2fl/fl)
den neuralen Stammzellpool des Gyrus Dentatus, in Vergleich zu
einen chd7 Einzel-Knockout, retten.
Diese Ergebnisse führten zu ersten Behandlungsversuchen CHD7
defizienter Stammzellen in vitro und in vivo mit einem sehr potenten
EZH2 Inhibitor.
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1 Introduction
1.1 Epigenetic active Proteins and their Modifications
Pluripotent stem cells develop into various cell types and tissues during
the embryonic development. Gene expression patterns between different
cells types containing the same DNA, are established through a coordi-
nated process of transcriptional components and changes in the chromatin
structure. To mediate these changes, chromatin remodeling enzymes
interact with the assembly and compaction of chromatin.
Chromatin is formed by DNA and protein nucleosomes consisting of
eight histone proteins, wherein each histone is surrounded by 147 base
pairs of DNA. A nucleosome contains two copies of each core histone H2A,
H2B, H3, H4 and a variable amounts of biochemical variants, which differ
only in a few amino acids. The DNA/ histone interaction is stabilized
by about 142 hydrogen bonds, hydrophobic interactions and charging
differences between the positive charged lysins and arginines of the
histone, and the negative charged phosphodiester backbone of the DNA.
The nucleosome complex, when further stabilized by the linker histone
H1, condensates the linear DNA molecule around 30 to 40-fold (Luger et
al., 1997).
As a part of the nucleosome, N-terminal histone residues protrude
out of the histone/DNA structure and are thus accessible to chemical
modifications like acetylation, methylation, phosphorylation, sumoy-
lation, ubiquitylation, ribosylation and glycosylation (Zink and Paro
1989) (Fig. 1). These modifications are mediated by enzymes which
have been conceptualized by their biochemical task as reader, writer and
eraser. Readers are distinct effector proteins which recognize for example
specific methylated lysines depending on the neighboring amino-acid
sequence and methylation state (Hyun et al., 2017). Enzymes categorized
as writers, set chemical histone marks such as acetyltransferases (HATs),
lysine methyltransferases (KMTs), and ubiquitylation enzymes (E1, E2
and E3 enzymes), or phosphokinases while erasers work primarily as
lysine demetylases (KDMs), deubiquitinases (DUBs), histone deacetylases
(HDACs), or phosphatases (Chen and Dent, 2014; Kolybaba and Classen
2014, Valencia and Kadoch, 2019).
The functions of these histone modifications are thought to be pre-
determined by the structural effect to the histone/DNA structure. Covalent
histone modifications can change the charge and structural properties of
the nucleosome and therefore open or restrict the access to the DNA (Wood
and Shilatifard 2004). As a consequence, genes of the before blocked DNA
1.1 Epigenetic active Proteins and their Modifications 6
Figure 1: A mammalian histone octamer of histone H2A, H2B, H3 and
H4 and their N-terminal residues. Mentioned are the amino acids that
are known to be modulated and the modifications for each amino acid
(methylation, acetylation, ubiquitination or phosphorylation). Modified af-
ter Wood and Shilatifard 2004.
region can be actively transcribed again, or their transcription can be
blocked and genes thus be silenced.
Typically, the tri-methylation of Lys 4 in H3 (H3K4me3), together with
histone acetylations are associated with active transcription (Gaspar-Maia
et al., 2011). The methylations of H3K4, H3K36 and H3K79 are considered
to mark active transcription, whereas H3K9, H3K27me, H3K27me2 and
H3K27me3 and H4K20 methylations are thought to be associated with
transcriptional repression and a silenced chromatin states, although in
some cases mediated through the recruitment of distinct silencing factors
(Schuettengruber et al., 2011; Black et al., 2012; Chen and Dent, 2014) (Fig.
1).
Other mechanisms refining the epigenetic landscape include the in-
corporation of histone variants like H3.3, H2AZ or macroH2A (discussed
elsewhere), and DNA modifications. DNA modifications are chemi-
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cal alterations on DNA rich in Cytosine and Guanine, so called CpG1
sites which can be methylated directly. The so called 5-methylcytosine
and its derivates, 5-hydroxymethylcytosine, 5-formylcytosine and 5-
carboxylcytosine are the most studied DNA modifications (Kohli and
Zhang 2013). DNA CpG methylations are conducted by DNA methyl-
transferases (DNMTs) and repress the gene expression (Gaspar-Maia et
al., 2011). The persistence of DNA methylation signals over several DNA
replication steps could be reported in the last years. Cytosinemethylation
marks are divided during S-phase in a semiconservative manner (Kolyaba
and Classen 2014). Besides these cytosine methylations, newer studies
found a N6-methyldeoxyadenosine (6mA) known from prokaryotes, in the
early phases of vertebrate embryonic development (Liu et al., 2016).
The DNA-histone interaction can be disrupted by chromatin remod-
eling enzymes sliding nucleosomes along the DNA, or translocating the
nucleosome core particle to another DNA strand. It is thought that DNA
parts sterically hindered by the nucleosome structure surrounding it,
could be re-accessible after sliding the nucleosome to another position,
and thus making room for transcription factors (Smith and Peterson, 2005).
This process is guided by the different chromatin marks which are read by
protein domains of the chromatin remodeling enzymes. The exchange of
histones and reposition or eviction of nucleosomes is mediated through
ATP consumption. The general working mechanism for ATPases and
similar functioning helicases are repeated circles of enzymatic opening
and closing over the DNA, which allows the enzyme to move along
single-stranded DNA or RNA (Singelton et al., 2007; Chen and Dent, 2014).
1.1.1 ATP-dependent Chromatin-Remodeling Complexes and the CHD
Family
Based on similarities of ATPase subunits genes, the chromatin remodeling
complexes have been grouped into four main families: SWI/SNF (mating
type switching/sucrose non-fermenting), ISWI (imitation switch), INO80
(inositol), and CHD (chromodomain helicase DNA-binding) proteins
(Winston et al., 1992; Marfella and Imbalzano, 2007; Schuettengrube et al.,
2011; Gaspar-Maia et al., 2011; Chen and Dent, 2014).
The yeast SWI/SNF (switch/sucrose nonfermentable) family contains
a bromodomain, which recognizes the acetylated lysine residues on the
N-terminal tails of histones. This group consists of yeast SNF2 and STH1,
Drosophila melangaster Brahma (BRM), mammalian BRM (SMARCA2) and
1p refers here to the phosphodiester bond that links a cytosine and a guanine
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brahma-related gene 1 (BRG1 or SMARCA4). BRG1 is also the catalytic
subunit of the PBAF remodeler (Marfella and Imbalzano, 2007; Bultman et
al., 2000; Moshkin et al., 2007).
The ISWI family is characterized through their SANT domain, which
is named after the first proteins identified with this domain; Swi3, ADA2,
N-CoR and TFIIB and functions as a histone-binding module. This family
comprises yeast Isw1, Isw2 and mammalian homologues SNF2H and
SNF2L (Tsukiyama and Wu, 1995; Marfella and Imbalzano, 2007; Schuet-
tengruber et al., 2011).
The INO80 family can form three different complexes: INO80,
SNF2-related CBP activator protein (SCARP), and TAT-interacting
protein(TIP60)-p400. Members of this family have a DNA helicase activity,
they are involved in DNA repair and replication, and an evolutionary
conserved function of INO80 family members is chromatin editing. The
mammalian INO80 chromatin remodeler has further been linked to DNA
repair and especially interstrand cross-linking checkpoint activation
(Marfella and Imbalzano, 2007; Fazzio et al., 2008; Gaspar-Maia et al., 2011;
Andreev et al., 2019).
The CHD family includes a number of proteins which are highly
conserved from yeast to humans (Marfella and Imbalzano, 2007). It
comprises ATP-dependent chromatin remodeling enzymes, and is charac-
terized by its tandem chromodomains, helicase domain, and DNA-binding
domain (Manning and Yusufazai 2017). Chromodomains were originally
characterized in Drosophilas heterochromatin protein 1 (HP1) which binds
nucleosomes through its chromodomain and contribute to promotion of
closed chromatin states (heterochromatin) at homeotic genes (Pearce et al.
1992; Wreggett et al. 1994).
The CHD family consists of nine protein members, further distributed
into three subfamilies according to their structural homology. Two
chromodomains binding methylated histone-residues, and two Sucrose
NonFermentable2 (SNF2)-like helicase-ATPase domains are characteristic
for all CHD proteins (Hall and Georgel 2007; Layman et al., 2010). The
SNF2-like ATPase domain contains conserved amino acids which were
found in proteins involved in a variety of cellular processes including chro-
matin assembly, transcription regulation, DNA repair, DNA replication,
development and differentiation (Tsukiyama, 2002; Smith and Peterson,
2005; de la Serna et al., 2006; Marfella and Imbalzano, 2007) (Fig. 2).
CHD1 and CHD2 are grouped together because both proteins posses
a DNA-binding domain. CHD1 binds globally to active euchromatin and
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co-localizes with RNA polymerase II in embryonic stem cells (Gaspa-Maia
et al., 2009). Further, CHD1 is part of the acetyltransferase SAGA and SILK
complex in yeast (Pray-Grant et al., 2005), it interacts with trimethylated
histone 3 Lysine 4 (H3K4me3) in embryonic stem cells, and plays together
with CHD2 an important role in maintenance and development (Lalani
et al., 2005). Interestingly, the HDAC activity of CHD1 has been shown
to function as both transcriptional activator (Stokes and Perry, 1995) and
repressor (Tai et al., 2003) in mouse. A homozygous knock-out of chd1 is
perinatal lethal in mice (Marfella e t al., 2006). Embryos with CHD1 deple-
tion through RNA interference accumulate high levels of heterochromatin
and cannot differentiate (Gaspar-Maia et al., 2011). A newer study linked
CHD1 to learning and memory through Controlling the immediate early
gene response in the hippocampus (Schoberleitener et al., 2019). CHD2 is
found in iPS cells and mesenchymal stem cells and interacts besides the
histone variation H3.3 also with HDAC1 and 2 and the NCoR complex
(Micucci et al., 2015).
Instead of a DNA-binding domain CHD3, CHD4 and CHD5 contain
two tandem plant homeodomains (PHDs), which are zink finger motifs
able to interact with methylated histone residues (Bienz 2006). CHD3 inter-
acts with HDAC1/2, ATR and TRIM27. CHD4 was found in hematopoietic
and neural stem cells, and interacts with the nucleosome-remodelling
(NuRD) complex and binds specifically to H3K4 and H3K9me3 (Xue et al.
1998). CHD3 and 4 are part of the Mi2-NuRD (Mi-nucleosome remodeling
deacetylase) complex and as such, involved in transcriptional regulation,
replication, DNA repair and cell fate. As Mi-2alpha (CHD3) and Mi-2beta
(CHD4) they mediate the ATP-dependent nucleosome remodeling quality
of this complex (Tong et al., 1998; Zhang et al., 1999; Xue et al., 1998). A
double homozygous knock-out of chd5 is viable in mice. CHD5 interacts
with NuRD and binds to H3K4 and H3K27me3 (Micucci et al., 2015). A
depletion of CHD5 in the developing neocortex blocks neuronal differen-
tiation, and leads to an accumulation of undifferentiated progenitor cells
(Egan et al., 2013).
The group III of CHD proteins comprises CHD6, 7, 8 and 9 due to
their C-terminal tandem Brahma and Kismet (BRK) domains, but these are
functionally not fully understood (Daubresse et al. 1999; Micucci et al.,
2015; Manning and Yusufyai, 2017). These CHD proteins are homologues
of the Drosophilas protein Kismet which catalyzes the trimethylation of
H3K4, and directs ASH1 and TRX to chromatin (Klymenko and Mueller,
2004).
CHD6 to CHD9 use a SANT domain to bind nonspecific to DNA, and
especially linker DNA between nucleosomes (Schusterand and Stoeger
1.2 CHD7 and CHARGE Syndrome 10
2002; Aasland et al., 1996; Boyer et al., 2004). CHD6 interacts with RNA
Polymerase II, and is a DNA damage response factor stabilized during
oxidative stress via reduced degradation (Moore et al., 2019). CHD6 seems
to disrupt nucleosomes in a distinct non-sliding manner. CHD6 and 7 have
a reported affinity for shorter linker DNA, while CHD8 binds longer pieces
and thus slides nucleosomes into positions with more flanking linker DNA
(Manning and Yusufzai, 2017). In oligodendrocytes stage progression a
newer study reported a compensatory mechanism of CHD8 for CHD7
with common binding profiles (Marie et al., 2018). CHD9 is involved in
the osteogenic differentiation in human (Shur et al., 2005; Shur et al., 2006).
A chd6 and chd9 knock-out seems to have no effect (Manning and
Yusufzai, 2017). In contrast to that, knocking out chd8 causes autism
spectrum disorder (Manning and Yusufzai, 2017).
CHD7 over expression has been reported for aggressive subtypes of
breast cancer, stomach and colon cancer and glioblastoma (Kim et al., 2011;
Chu et al., 2017; Machado et al., 2019). Remarkably, a homozygous knock-
out of chd7 is lethal (Hurd et al., 2007) while a heterozygous mutation
causes CHARGE syndrome (Hall, 1979; Hittner et al., 1979; Pagon et al.,
1981) (Fig. 2).
1.2 CHD7 and CHARGE Syndrome
The mammalian chromodomain helicase DNA binding protein 7(CHD7)
protein structure consists of two chromodomains, an SNF2 domain, the
helicase - and two BRK domains (Liu et al., 2013). Although CHD7 is
highly conserved in mice (identity 94.9 and 97% similarity) one study
reports one chromodomain in mouse CHD7 (Marfella and Imbalzano,
2007), while other studies identify two chromodomains (Bosman et al.,
2005).
Located on chromosome 8q12.1, the Chd7 gene is 188 kb in size and
codes with 37 coding and non-coding exons for 2997 amino acids (Visser et
al., 2004).
In the developing embryo CHD7 is essential for the formation of
embryonic derived ectodermal neural crest cells (Schulz et al., 2014) which
migrate from the neural tube to the periphery to form for example heart
and brain. CHD7 binds multiple subunits of the PBAF complex in neural
crest cells. In mouse embryonic stem cells and neural crest cells, CHD7 was
enriched at enhancer regions, together with H3K4me1 (Gaspar-Maia et al.,
2011), and in both, Humans and Xenopus, CHD7 activates the transcription
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Figure 2: CHD family members in different stem cell types. Indicated are
CHD proteins with an either activating or inhibiting role in the develop-
ment of the mentioned stem cell population. Modified from Micucci et al.,
2015
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factors Slug, Twist and Sox9 which are critical for the migration of neural
crest cells from the border regions (Bajpai et al., 2010). CHD7 expression
is required in the surface ectoderm, endoderm, and migrating neural crest
cells which all contribute to the development of facial structures and the
eye (Sperry et al., 2015). Under healthy conditions CHD7 is expressed
in heart, optic vesicle, facio-acustic preganglion, brain, olfactory pit and
mandibular component of the first branchial arch of mouse embryos
(Lalani et al., 2005).
Furthermore, CHD7 interacts with p300, SOX2, an binds to Sox2, Oct4,
Nanog, Neurod, Rxrg, and Rarb (Micucci et al., 2015).
A homozygous mutation in the chd7 gene is lethal at E10.5 probably
due to respiratory and cardiovascular defects (Hurd et al., 2007), while a
heterozygous chd7 mutation causes CHARGE syndrome (also known as
Hall-Hittner syndrome). It has an estimated incidence of approximately
0.1-1.2 in 10,000 newborns (Blake and Prasad, 2006) and was named as
an acronym of the most prevalent birth defects (Coloboma of the eye,
Heart defects, Atresia of the choanae2, severe Retardation of growth and
development, Genital and Ear abnormalities) (Hall, 1979; Hittner et al.,
1979; Pagon et al., 1981).
The clinical features of CHARGE syndrome were graded into major
and minor diagnostic criteria. Coloboma of the eye, cranial nerve dys-
function, choanal atresia and ear abnormalities rated as major CHARGE
symptoms. Minor criteria are cardiovascular malformations, genital
hypoplasia, cleft lip/ palate, tracheoesophageal fistula3, distinctive face
characteristics, growth deficiency and developmental delay. Occasional
features are renal abnormalities, spinal abnormalities (scoliosis), fifth
finger clinodactyly4 and neck and shoulder anomalies (Blake et al.,
1998; Blake and Prasad, 2006). Other features associated with CHARGE
syndrome include late pubertal development, sleep apnea, intermittent
abdominal pain, retinal detachment, cataracts, migraines, seizures, urinary
tract infections, hypoglycemia and psychiatric and behavioral disorders
(Hartshorne et al., 2016).
Additionally, limb abnormalities, renal abnormalities and thymic hy-
poplasia were described5. Also defects in the olfactory bulb development
2A blockage of the passages between the nasal cavity and the naso-pharynx (Blake and
Prasad, 2006).
3tracheoesophageal fistula: is an abnormal connection between trachea and oesophagus
4clinodactyly: a curving of the fifth, small finger towards the fourth finger
5(Opthalamic Genetic Disease: A Quick Reference Guide to the Eye and External Ocular
Adnexa, by N.L. Couser, Elsevier 2019).
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and the absence of the sense to smell (Anosmia) appear to be present
in virtually all CHARGE patients (Vissers et al., 2004; Jongmanns et al.,
2008). A reduced or absent olfaction is often caused by hypoplasia or
aplasia of the olfactory bulbs. Even chd7 heterozygous knock-out mice
show a lack of odor discrimination and hypoplasia of the olfactory bulbs.
In olfactory tissue CHD7 colocalizes with Ascl1 and Neurod1 and thus is
highly expressed in olfactory epithelium (Micucci, et al., 2015).
However, clinical features in CHARGE syndrome vary from case
to case in their symptomatic severity and are incomplete penetrant in
humans (Layman et al.,2010; Nishina et al., 2012). In one example of two
monozygotic twin sisters and a siblings pair of two brothers, identical chd7
mutations resulted in a striking intrafamilial variability (Jongmans et al.,
2006).
The above described clinical features of CHARGE syndrome were
later related to chd7 mutations. Depending on the symptoms used as
selection criteria, 70 to 90% of the CHRAGE patients carry a chd7 mu-
tation6. Up to now, 554 pathogenic chd7 mutations of 894 patients have
been reported7. Some resulting in nonsense mutations (44%), frame shift
mutations causing deletions or insertions (34%), mutations in the splicing
site (11%) or missense mutations (8%) (Janssen et al., 2012). A study
analyzing the different chd7 mutations in humans, predicted a premature
protein truncation in 73% of analyzed patients. They include nonsense
and frameshift mutations, and conclude this would most likely lead to
haploinsufficiency of the CHD7 protein (Lalani et al., 2005). Newer studies
also analyze intronic chd7 mutations and indeed one study found that an
insertion of 63 nucleotides into intron 28 created a premature termination
codon, and a truncated protein (Villate et al., 2018).
Most of the described chd7 mutations are thought to be de novo mu-
tations, as most individuals diagnosed with CHARGE syndrome seem to
have unaffected parents (Liu et al., 2014, Pranckeniene et al., 2019). There
are however a few reported cases of inherited familiar chd7 mutations, with
parent-to-child transmission of non-mosaic chd7 mutations and CHARGE
syndrome (Jongmans et al., 2008; Hartshorne et al., 2016). In cases of af-
fected parents a chd7 mutation is autosomal dominant (Jongmans et al.,
2008). Thus, the estimated chances of transmitting a chd7 mutation to the
next generation is 50% but because of the large variability of the clinical fea-
tures the symptomatic severity for the offspring cannot be predicted (Jong-
6A heterozygous mutation of chd7 can also be found in a minority of Kallmann syndrome
patients (Bergman et al., 2011; Kim et al., 2008).
7Janssen et al., 2012 created a chd7 database (https://molgenis51.gcc.rug.nl/menu/main/home)
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mans et al., 2006; Jongmans et al., 2008; Bergmann et al., 2011).
Interestingly, somatic mutations and germline mosaicism8 have been
described in the context of CHARGE syndrome9(Jongmans et al., 2008;
Pauli et al., 2009). Germ line mosaicism was found in a father of two
affected children, carrying the same chd7 mutation causing CHARGE syn-
drome. This mutation could not be found in somatic lymphocytes but in
the spermatozoa of the father (Pauli et al., 2009). A somatic mutation in the
lymphocytes of an unaffected father could be related to the chd7 mutation
of two affected siblings (Jongmans et al., 2008). In this reported case the
gametes were not analyzed suggesting likewise a germline mosaicism of
the father which was passed along.
1.2.1 Eye Malformations in CHARGE Syndrome
Almost 80% of CHARGE patients show eye malformations and/or suffer
from blindness10. Among the most prevalent ocular features of CHARGE
syndrome are bi- or unilateral ocular colobomata, which describes a hole
in the iris, retina or choroid structure which arrises due to a failure in the
optic fissure closure (Bardakjian et al., 2004). The optic fissure is a ventral
groove that forms during optic cup morphogenesis. After the blood vessel
formation, the optic fissure closes around them. The mechanisms under-
lying optic fissure closure are poorly understood (Weiss et al., 2012) (Fig. 3).
Initially, the cells of the early optic vesicle express transcription factors
like Otx2, Pax6, Rx, Six3, Six6, and Lhx2 (Fuhrmann, 2010; Beccari et al.,
2013). These cells further differentiate into the retina pigment epithelium
(RPE), the neural retina, and the optic stalk (Fuhrmann, 2010). The regula-
tory mechanisms underlying neural retina morphogenesis and patterning
are not fully understood (Martinez-Morales et al., 2017).
Interestingly, an expression of CHD7 could be found in the developing
eye at E11.5 already (Sperry et al., 2015). At E12.5 the lens vesicle and
the neuroectodermal layer of the developing eye express CHD7 (Bosman
et al., 2005). The neuroectoderm forms the neural retina, retinal pigment
epithelium and the iris. Besides that, the eye is surrounded by a layer of
neural crest cells forming the sclera, the choroid and a part of the cornea
(Fig. 4). These neural crest cells help direct the generation of the optic
cup, which involves a complex folding process resulting in formation of the
choroid fissure (Sperry et al., 2015). CHD7 has reportedly been expressed
8Germline mosaicism where only some of the parental gametes carry the mutation while
the somatic cells (often used for genetic testing) have a non mutated genotype
9also in Lalani and Belmont 2009, Enz. of Molecular Mechanisms of Disease
10Database for ocular diseases (University of Arizona): CHARGE syndrome
1 Introduction 15
Figure 3: The development of mammalian eyes. The mammalian eye de-
velops as optic vesicle out of the prosencephalon (diencephalon). At em-
bryonic day 8 (E8) the optic vesicle is formed. Later on the optic vesicle
invaginates to form the lens pit and optic cup. The ocular surface ectoderm
forms the lens placode which invaginates to the lens pit soon after (E10.5).
At embryonic day 11 (E11) the lens pit is completely invaginated to build
the lens vesicle, placed on top of the optic cup. Above this structure the
cornea epithelium is closed. Neural crest-derived periocular mesenchymal
cells periocular mesenchymal cells migrate between the premature lens and
the cornea epithelium. The lens and optic nerve is further specified and
the retina and retina pigment epithelium (RPE) are build (E12.5 and E14).
In the adult eye the cornea has three layers: the cornea epithelium, the
stroma and corneal endothelium directly on top op the lens. The lens is
surrounded by the lens capsule. Secondary and primary lens fibers form
the core of the lens. Close to the cornea is the lens epithelium positioned.
Picture modified from lifemaps.com
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Figure 4: Ectodermal and neural crest tissue of the eyes. The embryonic
lens vesicle is build out of surface ectoderm, while the optic cup is build
out of neuroectoderm. In the adult eye the lens is formed out of surface ec-
toderm and the retinal pigment epithelium (RPE) and neural retina consists
of neuroectoderm. Neural crest cells build the sclera, cornea and choroid
(shown in white). Picture modified from Stenkamp, 2015
in neural crest cells (Randall et al., 2009; Bajpai et al., 2010, Schulz et al.,
2014). A loss of Chd7 within the retina contributes to ocular malformations
in mammals (Sperry et al., 2015).
Another study concluded that the eye development requires CHD7
in the surface ectoderm forming the lens, and in the neural ectoderm
building the optic cup and stalk morphogenesis. Further CHD7 would be
absolutely required for the specification of the neuraoectoderm (Gage et
al., 2015).
Intriguingly, the same chd7 mutation can affect the right and left eye
with different symptomatic severity. A study analyzing 53 CHARGE
patients diagnosed with chd7 mutations, were tested for their vision on the
right and left eye separately. Totally blind were 8% on the left, and 11% on
the right eye11(Hartshorne et al., 2016).
11Legally blind were the majority with 38% on the left eye and 21% on the right eye. A
moderate impaired vision reported 11% for their left eye and 19% for their right eye. Only
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A very frequently observed eye malformation in CHARGE patients
is, as mentioned before, the coloboma of the eye, originating from a non
closed optic fissure (Blake et al., 1998; Lalani et al., 2005; Hartshorne et
al., 2016; Nishina et al., 2012). Coloboma can affect virtually all struc-
tures of the eye. A coloboma of the iris results for example in a visible
key-hole shaped pupil (Bardakjian et al., 2004). The overall prevalence
of iris-, retina-, choroid-, disc colobomata in CHARGE syndrome was
rated between 77 and 90% in different studies (Blake et al., 1998; Lalani
et al., 2005; Hartshorne et al., 2016). A further study focussing on eye
malformations found a prevalence of 94% (18 out of 19) of patients with
coloboma and chd7 mutation. In total, 35 eyes displayed a coloboma of the
posterior segment and the anatomical severity of the eye malformations
were graded according to the presence of colobomata, macula12 defect, and
microphthalmos13. They observed that even eyes with large colobomata
could form maculas. Again, a low to moderate agreement between the
phenotype of both eyes was reported. The authors found a significant
correlation between the location of the CHD7 truncation, and the severity
of the eye symptomatic (Nishina et al., 2012).
Besides ocular coloboma CHARGE patients also often suffer from
retina detachment and cataracts (Hartshorne et al., 2016). More seldom
are optic nerve hypoplasia and hyperplastic viteous14 causing a turbidity
of the inner eye fluid due to a persistent fetal vasculature15. Additionally,
anophthalmia16, hypertelorism17 and ptosis18 are described19.
a mildly restricted vision had 17% on the left and 23% on the right eye and a normal vision
was reported for 19% on the right and left eye (Hartshorne et al., 2016)
12Macula: also called fovea; a spot on the retina consisting of mostly cone cells and
needed for sharp vision.
13Microphthalmia refers to a globe with a total axial length that is at least two standard
deviations below the mean for age (Bardakjian et al., 2004).
14Also known as persistent fetal vasculature (PFV) which is a developmental de-
fect first described by A.B. Reese in 1955 (American Journal of Ophthalmology, 40(3)
https://doi.org/10.1016/0002-9394(55)91866-3) as a congenital malformation of the ante-
rior portion of the primary vitreous.
15Database for ocular diseases (University of Arizona): CHARGE syndrome
16one or two missing eyes
17wide-spaced eyes
18a dropped eye lid
19In Opthalamic Genetic Disease: A Quick Reference Guide to the Eye and External Oc-
ular Adnexa, by N.L. Couser, Elsevier 2019
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1.2.2 Mental Impairments in CHARGE Syndrome
CHARGE patients show a broad spectrum of mental challenges and even
impairments, including e.g. developmental delay, autism spectrum, de-
pression, anxiety and hyperactivity. An early study reported low adaptive
behavior skills, motor impairments and moderate to strong autism spec-
trum disorder symptoms in 13 patients with CHARGE syndrome (Smith
and Peterson 2005). A very detailed study of the psychological symptoms
and behavioral traits in CHARGE syndrome reported a frequent develop-
mental delay in 85% of patients. Most patients reported sleeping problems
(59%) followed by aggressive behavior (51%), tactile defensiveness (51%),
obsessive compulsive (49%), or self-injuring behavior (47%), anxiety (45%),
attention deficit (26%), autism spectrum (26%)20. In this study CHARGE
patients gave a self-report on what decreases their life quality regarding to
their mental health. Besides insomnia, the feeling of anxiety and a poor
overall mental health restricted them the most (Hartshorne et al., 2016).
A study further underlining obsessive compulsive and repetitive
behaviors, and to less extend aggressive and auto-aggressive behavior in
CHARGE patients, reported an average of 11.5 repetitive behaviors per
patient per day. This compulsive behavior reportedly interfered with their
daily routine (Bernstein and Denno 2005).
A major difficulty of many human studies is to differentiate how the
different symptoms of CHARGE syndrome influence each other, and
how they intertwine. For example, patients suffering from deaf-blindness
might show decreased receptive language skills as a result of their dif-
ferent perception. It is undoubtedly difficult to Control against sensory
impairments when psychologically assessing human patients. An early
study empathized the challenges of diagnosing autism in individuals with
sensory impairments (Smith et al., 2005).
To decipherer the connections between hearing loss, cognitive abilities
and the quality of language perceptiveness, a study was conducted. Here
Vesseur and colleagues could connect the degree of hearing loss with
receptive and expressive language skills, and found a correlation between
the receptive language skills and the cognitive abilities. The cognitive
abilities were not connected to expressive language skills or the degree of
hearing loss. Interestingly, out of the 41 analyzed patients 58.5% scored
low on IQ tests (lower then 70)21(Vesseur et al., 2016). However, the type
20tics (17%), conduct disorder (13%), depression (8%) and other (8%) (Hartshorne et al.,
2016)
21Out of 41 patients with CHARGE syndrome 0 had an IQ over average (IQ bigger 115),
9 (22) had a normal IQ score between 86-115, 8 (19.5) had a subnormal IQ level between 70
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of IQ test used was not mentioned, thus it remains unclear wether sensory
impairments could influence the results. Furthermore, the possible visual
impairments (e.g. coloboma of the eye reported in 77 to 94% of patients
(Blake et al., 1998; Lalani et al., 2005; Nishina et al., 2012; Hartshorne et al.,
2016)) of the analyzed CHARGE patients were unfortunately left out of the
picture.
Another significant correlation was found between sleeping prob-
lems, anxiety, self-abuse, conduct problems and autistic-like behaviors in
CHARGE patients. The authors connect the sleeping problems with the
restricted vision and the possible influence on the melatonin release and
circadian rhythm (Vesseur et al., 2016), but not to the reported sleep apnea
which occurred in 25% of the cases (Hartshorne et al., 2016). However,
Vesseurs study focusses on CHARGE syndrome, so patients were not
grouped due to chd7 mutations but rather due to their symptoms. This is
especially disastrous because other mutations like a triplication of Sox11
and an inappropriate p53 activation during the development can mimic
clinical CHARGE features (Sperry et al., 2014; Nostrand et al., 2014).
1.2.3 Cerebellum under CHD7 Deficiency
The cerebellum is the center of motor function and locomotion Control
in the brain, and inhibitory signals of the cerebella Purkinje cells are the
main output of the cerebellum to other brain parts. A fully developed cere-
bellum is sagittally separated into anterior (lobules I-V), central (lobules
VIa to VII), posterior (lobules VIII) and nodular (lobules IX and X), while
the medial part of the cerebellum is called vermis. In 35% of CHARGE
syndrome patients a cerebella vermis hypoplasia has been reported (Yu
et al., 2013) and a newer case study reports a de novo duplication in the
chd7 gene causing mildly hypoplastic inferior vermis, and dilatation of the
lateral and fourth ventricles in a CHARGE patient (Pranckeniene et al.,
2019).
Cerebella hypoplasia has been recapitulate in mice studies, showing
that a loss of CHD7 can cause this phenotype (Feng et al., 2017; Whittaker
et al., 2016; Donovan et al., 2017). One study related midbrain and vermis
hypoplasia with a reduced FGF8 expression and postulates CHD7 as FGF8
regulator (Donovan et al., 2017).
Within the cerebellum CHD7 interacts with Top2B a topoisomerase
which is decreasing the tension during the transcription of long genes.
and 85 and 24 (58.5) scored low (less then 70) on IQ tests (Vesseur et al., 2016).
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Intriguingly Reelin was reported to be a target of CHD7. In the cerebellum
Reelin is released by granular neurons and secreted to Purkinje cells to
guide them into the right position. Under CHD7 deficiency the Reelin
gene shows a closed chromatin state (Feng et al., 2017) and the Purkinje
cell layer is disrupted (Feng et al., 2017; Whittaker et al., 2017).
In CHD7 deficient mice a reduced FGF8 expression in the isthmus
organiser (IsO), the embryonic signaling centre of the cerebellum has been
reported. During cerebella development fgf8 and chd7 loss-of-function alle-
les interact. Since CHD7 associates with otx2 and gbx2 regulatory elements
and alters the homeobox gene expression, it has been suggested that CHD7
is needed for maintenance of cerebella identity during embryogenesis (Yu
et al., 2013).
1.2.4 Stem Cells under CHD7 Deficiency
In embryonic stem cells the presence of CHD7 correlates with signals of
active gene expression and open chromatin. CHD7 is present at enhancer
elements of stem cell and pluripotency genes like sox2, oct4 and nanog. A
major co-localization of BRG1 and CHD7, distal but not proximal to gene
promotors was reported in embryonic stem cells. Common co-localization
sites of both proteins included master transcription factors of embryonic
stem cells, and genes associated with active chromatin architecture (Yang
et al., 2017).
In embryonically derived neural crest cells CHD7 binds multiple
subunits of the PBAF complex. In genes of the ectodermal linage CHD7
binds preferentially active (H3K4me1, H3K27ac) and poised (H3K4me1,
H3K27me3) enhancer elements (Zentner et al., 2011; Gaspa-Maia et al.,
2011). Ectodermal lineages and tissues are affected in CHARGE syndrome
including the brain, retina and neural crest-derived structures like heart
and craniofacial structures.
Some developed tissues still contain multipotent stem cells. In the
adult brain, multipotent neural stem cells are located in the subventricular
zone of the lateral ventricle and migrate as neuroblasts through the rostral
migration stream into the olfactory bulbs to form new interneurons. An-
other stem cell niche of the adult mouse brain is the hippocampal dentate
gyrus which is functionally involved in learning and memory. Neural
stem cells of the dentate gyrus migrate from the subgranular zone into the
granular layer to form granular neurons (Fig. 5). In rodents 85% of dentate
granular neurons form and connected to hilar mossy fibers postnatally
(Ribak et al., 1985). In contrast to that, human granular neurons of the
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Figure 5: Neural stem cell niches in the adult mouse brain. Modified after
Zhao et al., 2008
dentate gyrus are formed prenatally (E90), and connect to hilar mossy
fibers around E160 to 170 (Humphrey 1967).
CHD7 is highly enriched in neurogenic regions of the adult mouse
brain, the subventricular zone, the rostral migratory stream and the
subgranular zone. Long time studies with an inducible, conditional
knock-out of chd7 in adult neural stem cells of the subventricular zone
showed that CHD7 deficiency lead to a reduction in mature dopaminergic
and GABAergic olfactory bulb interneurons. The effect of this knock-out
is the downregulation of the CHD7 targets sox4 and sox11 in combination
with an accelerated proliferation of the stem cell pool. In the SGZ of the
hippocampus less BrdU-positive newborn neurons have been found (Feng
et al., 2013).
In neural stem cells CHD7 physically interacts with the SOX2 at genes
involved in diseases like Alagille syndrome (jag1, a Notch signaling
ligand), Feingold syndrome (mycn, a bHLH transcription factor) and
Pallister-Hall syndrome (gli3, a mediator of sonic hedgehog signaling).
Furthermore, these diseases show a symptomatic overlap with CHARGE
syndrome. Both CHD7 and SOX2 have overlapping expression patterns
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and functions and contribute to the development of the ectodermal linages
including brain, retina and neural crest-derived cells (Micucci et al., 2015).
A study of oligodendrocyte precursor cells could show that CHD7 and
CHD8 functions overlap. CHD7 was found to Control oligodendrocyte
differentiation through chromatin opening and transcriptional activation
of key regulators. During cell state progression CHD7 seemed dispensable
because CHD8 compensated in chromatin binding profiles, and genetic
interactions (Marie et al., 2018).
CHD7 has been linked to an osteoblast cell fate decision in mesenchy-
mal stem cells. Here CHD7 represses PPAR-γ through a Wnt-mediated
mechanism and recruitment of a CHD7, NLK and SETB1 complex. Under
CHD7 deficiency this study could show that cells were taking a different
fate reasonably through PPAR-γ activity (Takada et al., 2007).
1.3 Epigenetic Proteins with Antagonistic Functions
After the discovery of polycomb as Controlling factor of the segmentation
in Drosophila (Lewis, 1978) the first hints to another group of chromatin
modifying proteins were collected in 1985 (Ingham 1985; Kennison and
Tamkun 1988). The transcriptional repressive polycomb (PcG) and the
(re)activating trithorax group (TrxG) of proteins, were identified as master
regulators of homeotic transcription factors or Hox genes (Lewis, 1978; Zink
and Paro 1989). These homeotic transcription factors determine the anterior-
posterior body axis during the embryonic development in vertebrates and
invertebrates.
Since then an antagonistic relationship between the trithorax and
polycomb group of proteins has been suggested (Klymenko and Mueller
2004; Dorighi and Tamkun 2013; Schuettengruber et al., 2017 review,
Micucci et al., 2015).
The trithorax group of proteins in Drosophila and the mammalian
myeloid/lymphoid or mixed-lineage leukemia (MLL)-protein-containing
complexes activate the same target genes, which are silenced by polycomb
group proteins. This is mediated through active histone marks such as
methylation of histone 3 lysine 4 (H3K4me3), and the dimethylation of
histone 3 lysine 36 (H3K36me2) (Dorighi and Tamkun 2013).
A double knock-out of ash2 and trx in Drosophila causes a loss of Hox
gene expression. This phenotype could be restored through the addition-
ally knocked-out of the polycomb counterpart PcG. ASH1 and TRX are
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concluded to be anti-repressors and trithorax and polycomb are described
as antagonistic regulators (Klymenko and Mueller, 2004).
A very interesting study emphasizes and antagonistic relationship of
trithorax and polycomb group proteins in mice. The mammalian MLL,
a homolog of Drosophilas TRX shows an axial-skeletal phenotype when
knocked-out and an altered Hox gene expression in mice. When this
knock-out was coupled to its polycomb counterpart bmi-1 and deleted
together, the phenotype normalized (Hanson et al., 1999).
In neural stem cells the trithorax member CHD4 interacts with the
polycomb group protein PRC2. CHD4 is expressed during neurogenesis of
the cortex, and expressed in murine SVZ neural progenitor cells. Intrigu-
ingly CHD4 interacts here with Polycomb repressive complex 2 (PRC2) and
especially its catalytic part enhancer of zeste (EZH2). PRC2 usually represses
gene expression on a broader scale through the trimethylation of histone
3 lysine 27 (H3K27me3) mediated by EZH2. However, in complex with
CHD4 it binds to the promotor of the glia fibrillary acidic protein (GFAP) to
suppress its expression and thus glia differentiation. In neural stem cells
CHD5 interacts with PRC2 and binds H3K27me3 as well (Egan et al., 2013;
Micucci et al., 2015).
Several PcG and TrxG proteins function as eraser proteins that prime
histones for the implementation of new histone marks. Many of these
eraser proteins are also found to be in complex with histone code writers,
facilitating immediate transition from active to inactive chromatin states or
conversely from inactive to active chromatin states (Kolybaba and Classen
2014).
A new study summarized the relationship of enzymatic histone marks
and their transcriptional activating or repressive effect (Fig. 6). As a
member of the CHD family CHD7 is related to a transcriptional active
chromatin state. A transcriptional repressive histone mark is set by the
writing enzyme EZH2, which is the catalytic part of the mammalian PRC2
complex.
1.3.1 Mammalian PcG Complexes and PRC2
There are five main PcG complexes in mammals that recognize and set
repressive histone marks: Polycomb repressive complex 1 (PRC1; Franke et al.,
1992), Polycomb repressive complex 2 (PRC2, Ng et al., 2000), dRing associated
factor complex (dRAF; Lagarou et al., 2008), Polycomb repressive deubiquitinase
complex (PR-DUB; Scheuermann et al., 2010), and Pho-repressive complex
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Figure 6: Chromatin regulatory mechanism mediating transcriptional ac-
tivation and repression Modified after Valencia and Kadoch, 2019
(Pho-RC; Klymenko et al., 2006). Additionally PRC3 and 4 are separated
by different EED isoforms (Kuzmichev et al., 2002 and 2004).
The human PRC2 complex consists of the proteins embryonic ectoderm
development (EED), suppressor of zeste (SUZ) 12, and the enhancer of zeste
EZH1 or 2. PRC2 methylates Lysine 9 of histone 3 and mediates mono-,
di- and trimethylation of H3K27 (Magueron et al., 2008). The methyl-
transferase activity of PRC2 is conducted by the SET domain of EZH2
and the resulting suppressive histone marks are needed for neural fate
commitment and terminal differentiation of neural stem cells during
embryonic development (Magueron et al., 2008).
1.4 EZH2 Deficiency causes Weaver Syndrome
The Enhancer of Zeste (E(Z)) was first identified in Drosophila as the catalytic
part of the PRC2. The mammalian (E(Z)) homologe EZH1 and 2 show
conserved domains like the homolog domain 1 and 2 (both needed for
protein-protein interactions), and the catalytic SET domain (Cao 2008).
In humans, the ezh2 gene is located on 7q35 with 20 exon’s. The protein
consists of 746 amino acids.
The pre-SET domain of EZH2 (and other members of the E(z) family)
contains a triangular zinc cluster that stabilizes the methyltransferase
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Figure 7: Mechanism of methyl group transfer to lysine residue used by
EZH2. Modified from Wood and Shilatifard, 2004
activity (Min et al., 2002; Wood and Shilatifard 2004). As methyltransferase
is EZH2 capable of transferring and erasing methyl groups, and uses
S-adenosylmethionine (SAM or AdoMet) as a methyl group donor. All
members of the mammalian DNMT family use SAM or AdoMet as donor
(which is synthesized from methionine). The catalytic mechanism of the
SET domain itself is mediated together with S-adenosylmethionine and the
substrate lysine of a histone tail. A conserved tyrosine of the SET domain
deprotonates the epsilon-amino group of the substrate lysine, and prepares
it therefore for a nucleophilic attack on the AdoMet methyl group (Trievel
et al., 2002). The methyl group is transferred to the lysine of the histone
tail, leaving a methylated histone residue and AdoHcy, the byproduct of
AdoMet which serves as potent inhibitor of methyltransferases (Hitchler
and Domann 2009; Jacobs et al., 2002; Min et al., 2002; Wilson et al., 2002;
Zhang et al., 2002). EZH2 is capable of mono- di- and tri- methylating
lysine 27 of histone 3 (H3K27me1,H3K27me2,H3K27me3) which silences
gene expression (Fig. 7).
EZH2 can also be inhibited by GSK126, a small molecule that is
competitive to S-adenosyl-methionine (SAM) and non-competitive with its
peptide substrates. GSK126 is highly selective against other methyltrans-
ferases. Even EZH1 which is 96% identical to EZH2, is inhibited 150-fold
less (McCabe et al., 2012).
In contrast to EZH2, EZH1 has only a weak catalytic function. The
PRC2-EZH1 complex seems to be involved in chromatin compaction and
it does not need the methyltransferase co-substrate SAM or AdoMet for
this activity (Magueron et al., 2008).
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A homozygous mutation is the ezh2 gene is lethal, while a heterozy-
gous mutation of ezh2 was linked to a medical condition called Weaver
Syndrome. Numerous de novo and familial missense mutations were
found. Their spacial distribution spreads all over the gene structure but
some cluster around the catalytic SET domain (Tatton-Brown et al., 2014).
These mutations are likely to form a non-functional protein which could
even build up artificial complexes. Besides a dominant negative effect of
the mutation, these mutations could also lead to a loss of function and
haploinsufficiency (Ronan et al., 2013,).
Patients with Weaver syndrome show an overgrowth phenotype in
90% of the cases and intellectual disabilities in more than 80% of cases.
Also, dysmorphic facial features, obesity and macrocephaly are common
symptoms (Tatton-Brown et al., 2013). In Weaver syndrome the methyl-
transferase activity of the whole PRC2 complex can be impaired (Gibson
et al., 2012). A ezh2 knock-out reportedly leads to impairment of spatial
learning and memory, contextual fear memory and pattern separation in
mice (Zhang et al., 2014).
1.4.1 EZH2 and PRC2 in Stem Cells and Differentiation
A knock-out of the complete PRC2 complex has no effect on early linage
commitment or embryonic stem cell self-renewal. Embryos that lack
PRC2 homozygously fail to pass midgestation and die during and after
implantation (Chamberlain et al., 2008; Shen et al., 2008; Pasini et al.,
2004; Morin-Kensicki et al., 2001). EZH2, EED and SUZ12 are essential
for the embryonic development, deficient mice are embryonic lethal and
EZH2-null or EED-null embryonic stem cells could not be established (Gil
et al., 2005; Pasini et al., 2007).
In the context of embryonic development and differentiation of stem
cells, a time dependent role of EZH2 has been described, because it has
been observed that EZH2 expression level drop during cell differentiation.
The role of PcG and especially EZH2 in neuronal progenitor cells seems to
be the refinement of cell fate commitment (Kuzmichev et al., 2005).
A time-dependent activity of EZH2 has also been reported for neocor-
tical neuronal progenitor cells. A knock-out of ezh2 lead to a prolonged
neurogenic phase and delayed the astrogenic phase. After embryonic day
12.5 a knock-out increased neurogenesis in the cerebral cortex through a
more rapid cell cycling of neural precursors which lead to an increase in
the number of neurons. The depletion of EZH2 in neuronal precursors
did not change their cell fate anymore after a critical time point. This
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was related to a lacking repression of the Wnt beta-catenin target Neuro-
genin1. In general, PcGs seem to regulate the differentiation capacity of
neuronal progenitor cells without affecting the differentiation process per
se (Hirabayashi et al., 2009).
Furthermore, EZH2 is expressed in actively dividing neural stem cells
and progenitors, but not quiescent neural stem cells in the subgranular
zone. Here EZH2 regulates the proliferation by suppressing PTEN ex-
pression and promoting the activation of the Akt m-Tor pathway (Zhang
et al., 2014) A regional loss of EZH2 in the stem cell niches affects the
differentiation of neural stem progenitor cells and the maintenance of the
stem cell population. In the subgranular zone of the dentate gyrus, an
increase in NeuN positive and a moderate increase in Nestin positive cells
was observed but no change in GFAP positive cells. It was concluded that
EZH2/H3K27me3 would play an important role in the maintenance of
stem cell subpopulations within the subventricular zone and the subgran-
ular zone of the dentate gyrus (Rhodes et al., 2018).
1.4.2 EZH2 in Cancer
Since the nature of histone mark H3K27me3 is to repress gene expression
an EZH2 deficiency has been linked to over proliferation and cancer.
Especially lymphoma, prostate and breast cancer were linked to reduced
EZH2 activity (Varambally et al., 2002).
Interestingly, loss of function and gain of function mutations in ezh2
seem to promote cancer growth an aggressiveness in a context dependent
manner. In a subset of hormone-refractory, metastatic prostate cancer high
EZH2 level were linked to clinical failure. It was traced back to EZH2 miti-
gating the G2/M transition in cell cycle (Cao et al., 2008). EZH2 was shown
to silence tumor suppressor genes (Chen 2010) and was therefore thought
to promote cancer growth when functionally impaired. In contrast to
that, McCabe and colleagues describe an over expression of EZH2 and an
H3K27me3 up-regulation in lymphomas and state that a different substrate
preference of the mutated protein could be the reason (McCabe et al., 2012).
In clear cell carcinoma an EZH2 Inhibitor caused regression and
reduced the number of tumor suppressor gene arid1a mutated tumors
(Bitler et al., 2015).
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1.4.3 EZH2 Phosphorylation
The EZH2 protein can be phosphorylated at different amino acids with
different effects. First, Riising et al. stated that a phosphorylation of EZH2
leads to a functional inhibition of both the recruitment to chromatin, and
the gene repressive activity (Riising et al., 2008; Chen et al., 2010; Kaneko
et al., 2010; Wei et al., 2011; Wu and Zhang 2011).
Then Chen et al. observed in more detail that CDK1 and 2 phospho-
rylate EZH2 at Thr350 is functional relevant for the recruitment to histone
and the H3K27me3 level (Chen et al., 2010). This phosphorylation of EZH2
through CDK1 and 2 represents an important link to the cell cycle.
Another link of EZH2 to cell growth and nutrient-response allego-
rizes the phosphorylation through Akt, a kinase of the phosphoinositide
3-kinase (PI3K) signaling pathway. Also in this case a phosphorylation
of EZH2 lead to a reduced methyltransferase activity and decreased
H3K27me3 level (Cha et al., 2005).
Different studies agreed that EZH2 phosphorylation increases its degra-
dation, followed by reduced H3K27me3 marks and interference with its
ability to bind to non-coding RNAs, such as HOTAIR and Xist (Chen et
al., 2010; Kaneko et al., 2010; Wei et al., 2011; Wu and Zhang et al., 2011).
In mouse embryonic stem cells the origin of EZH2 bound RNAs was fur-
ther investigated. It became clear that EZH2 preferentially binds to the
5’-region of RNAs originated from genes with low PRC2 occupancy and
low H3K27me3 level. The genomic origin of the bound RNAs was com-
pared to the distribution of bound PRC2 on the chromatin. PRC2 seemed
to bind preferentially to active promotors and interacted with their nascent
transcripts. RNA binding to EZH2 decreased H3K27me3 level at active
promotors which could hint to a molecular link between gene state and
epigenetic regulation (Kaneko et al., 2013).
1.5 Related Studies in Mice
A combined knock-out of mammalian trithorax and polycomb-group ho-
mologues was first described by Hanson et al. 1999. As mentioned before,
in this study mll a homologue of Drosophilas trx was knocked-out in combi-
nation with bmi-1 a homologue of Drosophilas polycomb member Posterior
sex combs (Psc). In this study, the Hox gene defects caused by a mll knock-
out were normalized in a combination with an bmi-1 knock-out in mice
(Hanson et al., 1999).
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1.5.1 CHARGE and CHARGE-like mouse lines
Different approached have been used to generate CHARGE and CHARGE-
like mice over the years.
While analyzing chromosome 4 mutants in head-bobbling mice with
circling behavior, six nonsense and three splicing site mutations of the chd7
gene were found. The expression of CHD7 in eye, olfactory epithelium, in-
ner ear and vascular system during the early development was confirmed
(Bosmann et al., 2005).
A gene trap null allele was generated through insertion of a lacZ
reporter into the chd7 allele creating a functional null allele coupled with
a ß-galactosidase reporter. CHD7 null mouse embryos died around E10.5
and heterozygous mice displayed CHARGE features (Hurd et al., 2007).
The so called looper mouse was identified by the ENU mutagen-
esis screen for deaf mice. The looper strain has a nonsense mutation
(c.5690C>A, p.S1897X) within the chd7 gene causing different symptoms.
These mice display ossicle malformation, otosclerosis and hearing im-
pairment, retarded growth, heart defect, hyperactivity and depending
on the used model eye coloboma. In behavior studies these CHARGE
mice circled in the arena and likewise in the water maze test. They
run faster and travel further than their Control litter mates. Since the
knock-out mice were falling less in the rotator experiment, it was con-
cluded that their motion Control itself was not impaired (Ogier et al., 2013).
A study analyzing a conditional neural crest cell knock-out of chd7
used Foxg1-Cre;Chd7+/flox and Wnt1-Cre;Chd7+/flox mice and analyzed
the skeletal phsnotype, the developing eye, ear, nose, pharyngeal pouch,
forbrain and gut (Sperry et al., 2015).
A later study analyzed the so-called trooper mouse, a mouse line har-
boring a pathogenic point mutation in the chd7 gene. This report focused
on middle ear defects and hearing impairment of mice, and showed that a
homozygous mutation remains lethal (Ogier et al., 2018).
Up to now, no Weaver disease mouse model (carrying a heterozygous
ezh2 mutation) has been described, but different ezh2 knock-out mouse
lines were created like the Pax7Cre;EZH2fl/fl mouse line (Feng et al.,
2016), or Ezh2flox/flox;ROSA26 mice (Rhodes et al., 2018).
A double knock-out of chd7 and ezh2 has not been described until now.
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1.5.2 Previous Data - chd7 and ezh2 Single Knock-out
Our pervious data showed that a chd7 knock-out in the cerebellum leads to
cerebella hypoplasia, impaired granular neuron differentiation, induction
of apoptosis and an abnormal Purkinje cell localization. We found that
CHD7 promotes the open chromatin state of genes like reelin which is
crucial for Purkinje cell development (Feng et al., 2017). Another study also
reported that a deletion of chd7 from cerebellar granule cell progenitors
results in reduced proliferation, cerebellar hypoplasia, developmental
delay, motor deficits and caused a downregulation of Reelin in mice
(Whittaker et al., 2016).
Interestingly, we further saw that CHD7 occupies active chromatin
regions (H3K27ac) (Feng et al., 2017). The opposite task namely H3K27
silencing via mono-, di- and tri-methylation is conducted by EZH2, the
catalytic part of the PRC2 complex. As described above a heterozygous
mutation in the ezh2 gene is related to a medical overgrowth condition
called Weaver syndrome. Also, the symptoms of CHARGE (CHD7+/d)
and Weaver syndrome (EZH2+/d) are partially oppositional.
Further hinting towards an antagonizing relationship of CHD7 and
EZH2, our data showed that a neural stem cell knock-out of chd7 increases
cell proliferation and decreases the stem cell pool (BrdU) in the dentate
gyrus. Strikingly, this phenotype could be rescued by voluntary running
(Feng et al. 2013) while physical exercise had no effect on the number of
stem and label retaining cells in an ezh2 knock-out conducted with the
same parameters (Liu, Y.).
A chd7 knock-out also affects the neuron morphology. Neurons with
chd7 knock-out show less and shorter branches (Feng et al., 2013) and
in contrast to that preliminary data showed that neurons with an ezh2
knock-out had more branches in comparison to littermate Controls (Liu,
Y.).
With these strong hints to an antagonizing relationship between CHD7
and EZH2, we hypothesize that EZH2 might be a good candidate to
counteract CHD7 mutation phenotypes.
1.6 Aims and Objectives of this Study
CHARGE syndrome is a combination of birth defects which can result
in a severe brain symptomatic that is currently not treatable. Patients
suffer from a broad spectrum of brain-related constraints and unlike other
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affected organs there is no surgery approach to ease the situation. A better
understanding of the disease related changes under CHD7 deficiency,
could enable the development of a stem cell treatment in the future. Thus,
a disease model of the CHARGE syndrome chd7 was analyzed. These
mice displayed a depleted stem cell pool in the dentate gyrus, a missing
cerebella anterior lobe and a disorganized cerebella purkinje cell layer
with less primary branches. Besides all that these mice had very severe eye
malformations.
Previous data suggested a possible antagonistic relationship between
CHD7 and EZH2. Following this hypothesis a genetic rescue of the
CHARGE mouse was analyzed and did proof that a reduction of both
CHD7 and EZH2 rescues the stem cell pool, the cerebellum and the eye
symptomatic almost entirely.
Furthermore, a inducible homozygous knock-out of chd7 and ezh2
restricted to neural stem cells, confirmed the rescue of the stem cell pool
and revealed that key regulators downregulated under CHD7 deficiency
were normally expressed in the double knock out.
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2 Results
2.1 The CHARGE Mouse
This mouse line was generated through crossing a CMVCre mouse line
carrying a Cre recombinase coupled to a universally expressed viral
CMV promotor (CMVCre, C57BL/6N-C2 mouse), with mouse line that
possessed a homozygously floxed CHD7 gene (CHD7fl/fl, C57BL/6N-C2
mouse). After the first mating the mutant mice of the F1 generation
expressed the Cre recombinase, and CHD7 heterozygous in all mouse
tissues from embryonic days onwards (CMVCre;CHD7+/fl). No crossing
within the mouse line was conducted.
A knock-out was confirmed after genotyping the tail DNA of the F1
litter, and further supported by analyzing the CHD7 expression in qPCR
and stainings of different tissues.
The absence of the human smelling sense is a known feature of
CHARGE patients, thus this tissue was examined. The olfactory bulbs of
CHARGE mice were smaller (Fig. 8 A and B) and the tissue expressed
significantly less CHD7. It has been shown before that a reduction of
CHD7 resulted in less newborn neurons in the olfactory bulbs (Feng et
al., 2013). In the CHARGE mouse line, a reduction in the doublecortin
expression could be observed, resulting in less newborn neurons in the
olfactory bulbs (Fig. 8D to K and L). These results confirm an efficient chd7
knock-out and the generated CHARGE disease model.
CHARGE patients are reportedly small, and some develop a micro-
cephalous. Therefore the body and brain weight of CHARGE mice were
measured and analyzed per mouse. Male and female mice were analyzed
separately. CHARGE mice of both sexes had a lower body weight in
comparison to the Control litter mates (Fig. 9A and B).
The total brain weight was quantified as percentage of the body weight
for each mouse. No significant changes were observed when all mice were
grouped together per sex (Fig. 9C and D). However, a selection of the most
severely affected mice did show a significant reduction in the brain weight
of these mice. Here the same number of male and female animals of both
genotypes was analyzed together.
Previous studies reported a hyperactive behavior of a mouse line
displaying CHARGE features (Ogier et al., 2013). Thus, the here analyzed
CHARGE mouse (CMVCre;CHD7+/fl) was examined in this regard. To
further analyze the movement and the running speed of the CHARGE
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Figure 8: CHARGE mice have deformed olfactory bulbs with less new-
born neurons. A and B: H & E stainings of the ten week old Control (CMV
Cre-) and CHARGE (CMVCre;CHD7+/fl) mouse olfactory bulbs. C: qPCR
for CHD7 expression in Control and CHARGE mouse olfactory bulb tissue;
n=3 animals per genotype, p=0.0433. D to G and H to K: Immunostainings
of DAPI, CHD7 and DCX in the olfactory bulbs of Control and CHARGE
mouse. L: qPCR of DCX expression in Control and CHARGE mouse olfac-
tory bulb tissue; n=7 Control and n=3 CHARGE mice, p=0.0189. Statistics
were done with a students t-test.
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Figure 9: CHARGE mice are smaller and severely affected mice have
a smaller brain. The ten week old Control (CMV Cre-), CHARGE
(CMVCre;CHD7+/fl) mouse were weight directly post mortem using a fine
scale. A: The weight of male animals of the Control and CHARGE mouse
line were compared; n=20 Control and n=9 CHARGE mice, p=0.0366. B:
The weight of female animals of the Control and CHARGE mouse line were
compared; n=4 Control and n=5 CHARGE mice, p=0.0330. C: The brain
weight of male Control and CHARGE mice were measured and calculated
in relation to their respective body weight; n=20 Control and n=9 CHARGE
mice, n.s. D: The brain weight of female Control and CHARGE mice were
measured and calculated in relation to their respective body weight; n=4
Control and n=5 CHARGE mice, n.s. E: Comparing the Control mice to
the three most severely affected CHARGE mutants; n=7 Control and n=3
CHARGE mice, p=0.0039. Statistics were done with a students t-test.
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mice, an open field test was conducted. Mice were filmed for 15 minutes,
and later analyzed by using a computer program (ImageJ macro, Fig. 10A
and B). The resulting excel sheets were used to calculate running speed and
traveled distance (Fig. 10C and D). Control mice were moving mainly at
the corners of the open field, while CHARGE mice did not spare the center
field (Fig. 10A and B). The chd7 mutant mice were traveling significantly
faster and further in comparison to their Control litter mates (Fig. 10C and
D).
2.1.1 Eye Defect in CHARGE mouse
CHARGE patients suffer from severe and diverse eye malformations in-
cluding complete blindness.
While the Control mice showed no eye abnormalities, the CHARGE
mice had mild to severe eye malformations with high penetrance. The
phenotype ranged from structural functionally eyes to a only rudimentary
developed eyes with closed eye lids. Virtually all mutant CHARGE mice
displayed some kind of eye malformation in one or two eyes (Fig. 11).
The eye symptoms showed a heterogeneity between the left and the
right eye.The CHARGE mouse eyes were scored regarding to their visible
closed eye lids (100% = eye completely closed, 50% = eye half closed, 0%
= not affected). On average the right eye was affected in 70% of the mice,
while the left eye displayed a closed eye lid in 30% of the mice. (Fig. 11).
Such a symptomatic heterogeneity in the severity of the eye phenotype has
been reported for human CHARGE patients likewise (Hartshorne et al.,
2016).
Further, the eye structure was analyzed. The eye of the Control animal
showed retina, lens, pupil and cornea and had a normal size of around
3 mm in diameter (Fig. 12A). The eye structure of the CHARGE mouse
eye is barely recognizable. Remarkably, a thick layer of black pigment
epithelium is surrounding the eye (under normal conditions the pigment
epithelium is forming a one-cell thick bottom layer underneath the retina).
The mutant eye has no visible pupil and the lens is not fully formed. A
retina is not recognizable. The eye is structural under-developed and
predictably non-functional (Fig. 12B).
Furthermore, the stained CHARGE eye was much smaller in its total
size in comparison to the Control mouse eye depicted on the left site (Fig.
12A and B). Only eyes with a visible pupil were analyzed, thus strongly
under-developed and structurally deformed eyes (like the one displayed)
were not included in this analysis. The eye diameter was measured with
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Figure 10: CHARGE mice run faster (Control and CHARGE mouse).
Eight week old Control (CMV Cre-) and CHARGE (CMVCre;CHD7+/fl)
mice spend 15 minutes in a 72 to 72 cm white box, moving freely while
filmed. A and B: An ImageJ macros was used to automatically track
the mice walking path in the box (developed by Yue Zhou). C: The
recorded distance traveled per minute; n=5 Control and n=6 CHARGE
mice, p=0.0487 between Control and CHARGE mouse. D: The overall dis-
tance traveled within 15 minutes each for Control and mutant mouse; n=5
Control and n=3 CHARGE mouse, p=0.0487. Statistics were done with a
students t-test.
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Figure 11: CHARGE mice have closed eye lids, more often on the
right site. The ten week old Control (CMV Cre-) and CHARGE
(CMVCre;CHD7+/fl) mice were photographed, and both eyes are shown
as zoomed picture of two example mice per genotype. The optically as-
sessable damage of the left and right eye was analyzed with 100% damage
representing a closed lid, 50% representing a half closed lid and 0% repre-
senting an open eye lid; n=7 CHARGE animals, and 7 left and right eyes
respectively (14 eyes).
2.1 The CHARGE Mouse 38
a scale tool of ImageJ. CHARGE mice had significantly smaller eyes in
comparison to their Control litter mates (Fig. 12C). Also the CHARGE eye
retina was significantly thinner than the retinas measured for their Control
litter mates (Fig. 12D).
To further investigate differences between the CHARGE and Control
mouse retina, the retina layers were stained and measured. Again, only
eyes with a visible pupil were considered, excluding the most severely
affected eyes. Therefore, the separation of the outer nuclear layer (ONL),
inner nuclear layer (INL) and granular cell layer (GCL) is visible in both
mutant and Control mice by the dark stained nuclei (Fig. 13A and B).
CHARGE mice displayed an outer nuclear layer thickness which was
comparable to the measured Control mouse retina thickness (Fig. 13C).
The inner nuclear layer of the retina was significantly thinner in the
CHD7 deficient mice (Fig. 13D).
There was no significant difference between the measured ganglion
cell layer thickness in Control and CHARGE mice eyes (Fig. 13E).
Since the severe CHARGE eye phenotype hinted towards underdevel-
oped eyes, markers were stained which are usually expressed early in the
eye development. Under-developed cells expressing embryonic markers
where not expected under Control conditions, and no MASH1 positive
cells where found. However, CHARGE retina showed cells with a signal
for MASH1 in the ganglion cell layer (Fig. 14B and F).
The Control retina displayed a clear PAX6 signal in the ganglion cell
layer and the inner nuclear layer, which corresponds to other studies
(Stanescu-Segal et al., 2015). Little is known about the function of PAX6
in the adult retina, but amacrine and ganglion cells keep the expression
under normal conditions (Stanescu-Segal et al., 2015).
Pictures of CHARGE mouse retina were taken with the same confocal
laser microscope adjustments but show a much weaker PAX6 signal. Only
very few cells can be considered as PAX6 positive (Fig. 14C and G).
2.1.2 Cerebella Defect in CHARGE Mouse
To confirm the chd7 knock out crebellum tissue of CHARGE
(CMVCre;CHD7+/fl) and control litter mates were stained for CHD7
and DAPI. The CHD7 signal in the CHARGE mouse cerebellum seems
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Figure 12: CHARGE mouse eyes are smaller and the retina is thin-
ner. A and B: The ten week old Control (CMV Cre-) and CHARGE
(CMVCre;CHD7+/fl) mouse eyes were stained with Hematoxylin and
eosin stain. Pictures were taken with a 1.25 x objective. C: The eye diameter
was measured with a scale tool of ImageJ; n=3 Control and n=6 CHARGE
eyes, p=0.0038. D: The retina thickness was measured with a scale tool of
ImageJ; n=6 Control and n=12 charge eyes, p=0.0038. N-values represent
eyes, more then 3 slices per eye were considered. Statistics were done with
a students t-test.
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Figure 13: CHARGE mouse retina has a thinner inner nuclear layer.
The ten week old Control (CMV Cre-) and CHARGE (CMVCre;CHD7+/fl)
mouse eyes were stained with Hematoxylin and eosin stain. A and B: H & E
Retina Staining of Control (left) and CHARGE (right) retina. Pictures were
taken with a 10 x objective. The retina thickness was measured with a scale
tool of ImageJ. C: Graph showing the measured outer nuclear layer (ONL)
thickness in µm for Control and CHARGE mouse; n=6 Control and n=12
CHARGE mouse eyes, n.s. D: Graph showing the measured inner nuclear
layer (INL) thickness in µm for Control and CHARGE mouse; n=6 Control
and n=12 CHARGE mouse eyes, p=0.0096. E: Graph showing the mea-
sured granular cell layer (GCL) thickness in µm for Control and CHARGE
mouse; n=6 Control and n=12 CHARGE mouse eyes, n.s. More than 3 slices
per eye were considered. Statistics were done with a students t-test.
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Figure 14: CHARGE mouse retina has less PAX6 positive cells and ex-
presses ectopic Mash1. A to H: The ten week old Control (CMV Cre-) and
CHARGE (CMVCre;CHD7+/fl) mice eyes were stained for MASH1 (white
arrows) and PAX6. Pictures were taken with a confocal microscope LSM780
(Zeiss).
reduced, indicating less CHD7 positive granular neurons (Fig. 15A to F).
The cerebellum tissue was homogenized and the RNA was isolated to
analyze the CHD7 expression. A qPCR showed a significant reduction in
the CHD7 RNA expression level under CHARGE conditions (Fig. 15).
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Figure 15: Immunofluorescence picture and qPCR graph for CHD7 in
the cerebellum (Control and CHARGE mouse) A to F: Stained brain
slices of the ten week old CHARGE mouse cerebellum were treated
with antibodies against CHD7 and DAPI and pictures were taken with
a laser microscope (LSM780, Zeiss). G: qPCR of CHARGE mouse cere-
bellum analyzing the relative expression level of CHD7 in Control
(CMVCre-) and mutant (CMVCre;CHD7+/fl) mice. n= four animals
per genotype. Statistics were done with a students t-test.
In some human CHARGE syndrome patients cerebella vermis hy-
poplasia has been reported (T. Yu et al. 2013).
Data from an Atoh1-Cre::Chd7fl/fl mouse line, showed a structural
difference in the cerebella anterior lobe (Feng et al., 2017). Thus, this
structure was analyzed in the CHARGE mouse.
An superior overview picture of the cerebellum tissue hinted already
towards a structural difference of the CHARGE mouse cerebellum (Fig.
16B and E) and a staining revealed that the III anterior lobe is missing in
the CHARGE mouse cerebellum (Fig. 16C and F).
The cerebellum was further analyzed with regard to the purkinje
cell layer. Strikingly the purkinje cell layer showed some a-typical cell
accumulations. While the Control animals had only 1.5% of Purkinje cells
with more than three neighboring cells, the CHARGE mutant mice had
27% of purkinje cells displayed three or more neighbors (Fig. 17C).
The Purkinje cell body size was measured but no significant difference
between the cell body size of Control and CHAGRE mouse could be
2 Results 43
Figure 16: CHARGE mouse has a defect in the anterior lobe of the cere-
bellum. A and D: Photograph of the brain of ten week old Control (CMV
Cre-) and CHARGE (CMVCre;CHD7+/fl) mice. Brains were placed next to
a scale, directly after dissection. B and E: Zoomed picture of the cerebellum
with marked V and VI lobe. The scale (mm) is indicated on the right. C
and F: Nissl staining of the medial cerebellum. Roman numbers indicate
the lobi. Ant = anterior, pos = posterior.
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observed (Fig. 17D).
Another characteristic of the CHARGE purkinje cells seemed inter-
esting. In the CHARGE animal, less calbindin positive cells appeared to
have primary branches. A quantification revealed that this difference was
significant (Fig. 17E).
2.1.3 Less Neural Stem cells in CHARGE Mouse DG
A loss of neural stem cells in the dentate gyrus has been linked to CHD7
deficiency before (Feng et al., 2013), thus the amount of BrdU and nestin
positive cells was analyzed, for cells grown under CHARGE and Control
conditions. The CHD7 mutant mice showed a significant lower number in
BrdU and Nestin double positive cells than their Control litter mates (Fig.
4.2.1).
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Figure 17: CHARGE mouse purkinje cells are disorganized and show
less primary branches. A and B: Stained brain slices of the ten week old
Control (CMV Cre-) and CHARGE (CMVCre;CHD7+/fl) mice cerebellum
were stained for Calbindin and DAPI, pictures were taken with a confocal
microscope LSM780 (Zeiss). C: Neighboring cells of each purkinje cell were
measured; n=347 Control and n=408 CHARGE mouse cells, p=0.0107. D:
Quantification of Purkinje cell-body size in Control and CHARGE mouse.
Cell-body sizes were measured using a scale tool of the ImageJ; n=33 Con-
trol and 37 CHARGE mouse cells, n.s. E: Purkinje cells with visible pri-
mary branches were manually quantified. Control Purkinje cells n=392,
CHARGE purkinje cells n=779, p=0.0344. N-values represent cell numbers
counted from different brain slices. Control Purkinje cells n=33, CHARGE
purkinje cells n=37 of three animals per genotype. Several stainings of three
mice per genotype were quantified. Statistics were done with a students t-
test.
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Figure 18: CHARGE mouse showed less stem and label retaining cells
in the dentate gyrus The ten week old Control (CMV Cre-) and CHARGE
(CMVCre;CHD7+/fl) mice were treated with BrdU for 5 days and dentate
gyrus were stained. A and B: Stained with BrdU, Nestin and DAPI and
pictures were taken with a laser microscope LSM780 (Zeiss). C and D:
Zoomed in pictures showing cells with BrdU and Nestin staining, marked
with white arrows. E: Graph depicting the counted cell amount of BrdU
and Nestin double positive cells [mm3]; n=7 Control and n=3 CHARGE
animals, p=0.0326. Statistics were done with a students t-test.
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2.2 The reCHARGE Mouse
To be able to compare the reCHARGE mouse line to the CHARGE mouse,
the same viral, universally expressed CMV promotor was used to knock-
out chd7 and ezh2 heterozygous in all cells of the body. The CMVCre
mouse line (C57BL/6N-C2 mouse) was crossed with CHD7fl/fl;EZH2fl/fl
mice (C57BL/6N-C2 mouse), to give birth to an F1 litter with the genetic
combination of CMVCre;CHD7+/fl;EZH2+/fl (herein interchangeably
called reCHARGE mouse, or heterozygous double knock-out). This
breeding scheme was used for all animals.
Illustrating the double knock-out of chd7 and ezh2 beyond the geno-
typing results, both proteins were stained in the cerebellum of Control,
CHARGE and reCHARGE mice. In combination with the purkinje cell
staining Calbindin, EZH2 staines purkinje cell nuclei, while CHD7 gives a
weak signal for granular cells, and no signal for purkinje cells (Fig. 19 A to
G).
To confirm a successful knock-out, EZH2 and CHD7 were an-
alyzed by a qPCR in the cerebellum tissue of reCHARGE mice
(CMVCre;CHD7+/fl;EZH2+/fl) and compared to Control (CMV Cre-)
and CHARGE mice (CMVCre;CHD7+/fl). While CHARGE cerebellum
tissue displayed a reduced CHD7 expression level in comparison to their
Control litter mates, the reCHARGE mouse cerebellum tissue confirmed
the double knock-out of chd7 and ezh2 (Fig. 19D and H).
As CHARGE mice weight less than their Control litter mates, the body
weight of the genetic rescue was determined. Males of both genotypes
had on average a weight of 23 grams, while the average female weight
was 19 grams. There was no detectable difference between reCHARGE
(CMVCre;CHD7+/fl;EZH2+/fl) and Control (CMVCre-) litter mated (Fig.
20A and B). In both male and female Control and reCHARGE mice no
difference between the measured brain weight could be observed (Fig. 20C
and D).
2.2.1 Eyes in CHARGE vs reCharge Mouse
The very severe and obvious eye malfomations of the CHARGE mouse
(CMVCre;CHD7+/fl) could not be observed in the reCHRAGE mouse
(CMVCre;CHD7+/fl;EZH2+/fl). While CHARGE mice often display
closed eye lids, the reCHARGE mice never showed such a pheno-
type. The eyes of littermate Control animals were optically indis-
tinguishable from the eyes of the heterozygous double knock-out
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Figure 19: reCHARGE mouse has a reduced expression of CHD7
and EZH2 in the cerebellum. A to C: The ten week old Con-
trol (CMV Cre-), CHARGE (CMVCre;CHD7+/fl) and reCHARGE
(CMVCre;CHD7+/fl;EZH2+/fl) mouse cerebellum were stained with
EZH2, Calbindin and DAPI. E to G: The cerebellum of all three genotypes
were stained for CHD7, Calbindin and DAPI. D: The qPCR was run using
Taqman probes of Actin, EZH2. Shown are the relative expression level
calculated by using the SQ values of samples with working standard, nor-
malized to actin; n=3 Control, n=4 CHARGE and n=4 reCHARGE mice,
Control to CHARGE n.s., p=0.0053 Control to reCHARGE. H: The qPCR
was run using Taqman probes of Actin and CHD7. Shown are the rela-
tive expression level calculated by using the SQ values of samples with
working standard, normalized to actin; n=3 Control, n=4 CHARGE and
n=4 reCHARGE mice, p=0.0097 Control to CHARGE, p=0.0055 Control to
reCHARGE. Statistics were done with a students t-test.
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Figure 20: reCHARGE mouse body and brain weight correspond to the
Control values. The ten week old Control (CMV Cre-), and reCHARGE
(CMVCre;CHD7+/fl;EZH2+/fl) mouse were weight directly post mortem
by using a fine scale. A: The weight of male Control and reCHARGE mouse
animals were compared; n=20 Control and n=9 reCHARGE mice, n.s. B:
The weight of female Control and reCHARGE mouse animals were com-
pared; n=4 Control and n=5 reCHARGE mice, n.s. C: The brain weight of
male Control and reCHARGE mice were measured and calculated in re-
lation to their respective body weight; n=15 Control and n=4 reCHARGE
mice, n.s. D: The brain weight of female Control and reCHARGE mice
were measured and calculated in relation to their respective body weight;
n=4 Control and n=5 reCHARGE mice, n.s. Statistics were done with a
students t-test.
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CMVCre;CHD7+/fl;EZH2+/fl (Fig. 21).
Hematoxylin and eosin stainings of Control, CHARGE and reCHARGE
eyes revealed that the heterozygous double knock-out had structural well
developed eyes; the reCHARGE eyes showed a retina, lens, pupil and
cornea. Even though, these eyes were bigger than the CHARGE mouse
eyes, they were still significantly smaller than the Control litter mate eyes
(Fig. 22A to D).
As seen before the CHARGE retina was thinner. In contrast to that the
reCHARGE retina was as thick as the Control mouse retina (Fig. 22E).
The retina layers analyzed in the CHARGE mouse line
(CMVCre;CHD7+/fl) were also analyzed in the genetic rescue
(CMVCre;CHD7+/fl;EZH2+/fl). All retina layers were stained and
measured (Fig. 23A to C). Remarkably some reCHARGE mice displayed
an extensive retina growth with a wavy structure (indicated in Fig. 23C).
Under CHARGE and reCHARGE conditions the outer nuclear layer
was not significantly altered in comparison to the Control values. How-
ever, the reCHARGE outer nuclear layer was significantly thicker than the
CHARGE outer nuclear layer but still corresponding to Control values
(Fig. 23C).
In comparison to the Control, the CHARGE retina had a reduced
inner nuclear layer thickness. In the reCHARGE mice the measured inner
nuclear layer thickness corresponded to the Control values (Fig. 23D).
The granular cell layer was not significantly changed in CHARGE or
reCHARGE mice. In this regard no significant difference between the
mouse lines could be observed (Fig. E).
Correlating to the presented CHARGE mouse results, the reCHARGE
retina was also stained for MASH1 and PAX6. Similar to the Control
mouse retina, the reCHARGE (CMVCre;CHD7+/fl;EZH2+/fl) had no
MASH1 positive cell (Fig. 24B and J).
The PAX6 signal observed for the reCHARGE retina is in comparison
to the signal detected under Control conditions much weaker. There are
no PAX6 positive cells in the granular cell layer, and only very few cells
can be considered positive in the inner nuclear layer of reCHARGE mouse
retina (Fig. 24C, G and K).
In summary, the reCHARGE eyes diameter was smaller than the Con-
trol eyes and the retina had a wavy structure which was more pronounced
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Figure 21: reCHARGE mouse eyes are unremarkable. The ten week
old Control (CMV Cre-), CHARGE (CMVCre;CHD7+/fl) and reCHARGE
mice (CMVCre;CHD7+/fl;EZH2+/fl) were photographed, and both eyes
are shown as zoomed picture of two example mice per genotype. The opti-
cally assessable damage of the left and right CHARGE mouse eye was ana-
lyzed with 100% damage representing a closed lid, 50% representing a half
closed lid and 0% representing an open eye lid; n=7 CHARGE animals, and
7 left and right eyes respectively (14 eyes). Control and reCHARGE mice
displayed no closed eye lids.
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Figure 22: reCHARGE eyes are smaller but structural unremarkable. A to
C: The ten week old Control (CMV Cre-), CHARGE (CMVCre;CHD7+/fl)
and reCHARGE (CMVCre;CHD7+/fl;EZH2+/fl) mice were stained with
Hematoxylin and eosin stain. D: Eye diameter was measured with a
scale tool of ImageJ; n=3 Control, n=12 CHARGE and n=6 reCHARGE
mouse eyes, p=0.0038 Control vs CHARGE mouse eye, p=0.011 Control
vs reCHARGE eye. E: Retina thickness was measured with a scale tool
of ImageJ; n=3 Control, n=12 CHARGE and n=6 reCHARGE mouse eyes,
p=0.0038 Control vs CHARGE mouse eye retina, Control vs reCHARGE
eye retina n.s. Statistics were done with a students t-test.
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Figure 23: reCHARGE retina corresponds to Control mouse retina A to
C: The ten week old Control (CMV Cre-), CHARGE (CMVCre;CHD7+/fl),
reCHARGE (CMVCre;CHD7+/fl;EZH2+/fl) mice were stained with
Hematoxylin and eosin stain and pictures were taken with a 10x objec-
tive. C: Graph showing the measured outer nuclear layer (ONL) thick-
ness in µm for Control, CHARGE and reCHARE mouse; n=6 Control, n=12
CHARGE and n=6 reCHARGE mouse eyes, n.s. D: Graph showing the
measured inner nuclear layer (INL) thickness in µm for Control, CHARGE
and reCHARE mouse; n=6 Control, n=12 CHARGE and n=6 reCHARGE
mouse eyes, p=0.0096 Control vs. CHARGE, Control vs reCHARGE n.s.
E: Graph showing the measured granular cell layer (GCL) thickness in µm
for Control, CHARGE and reCHARE mouse; n=6 Control, n=12 CHARGE
and n=6 reCHARGE mouse eyes, Control vs. CHARGE n.s, Control vs.
reCHARGE n.s. More then 3 slices per eye were considered. Statistics were
done with a students t-test.
2.2 The reCHARGE Mouse 54
Figure 24: reCHARGE retina has less PAX6 positive cells but not ectopic
MASH1 expression. The ten week old Control (CMV Cre-), CHARGE
(CMVCre;CHD7+/fl) and reCHARGE (CMVCre;CHD7+/fl;EZH2+/fl)
mouse retinas were stained for MASH1 (white arrows) and PAX6. Pictures
were taken with a confocal microscope LSM780 (Zeiss).
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in some individuals than in others. The inner nuclear layer corresponded
to the thickness of the Control mice retina and did not show a significant
reduction as the analyzed CHARGE retina did.
2.2.2 Cerebellum in CHARGE vs reCharge Mouse
Correlating to the obtained results for the CHARGE mouse cerebellum,
the overall structure of the reCHARGE cerebellum was analyzed. The
cerebellum tissue was from an apical point of view around 4 mm in size,
and the V and VI lobi was visible (Fig. 25A, B, D, E, G, and H).
A heterozygous double knock-out of chd7 and ezh2
(CMVCre;CHD7+/fl;EZH2+/fl) had in contrast to the CHARGE mouse no
abnormalities in the cerebella anterior lobe. Corresponding to the Control
cerebellum, the lobi III to X of the reCHARGE brain are clearly visible (Fig.
25I).
The purkinje cell layer which was under CHD7 deficiency
found to be disorganized, was analyzed in the reCHARGE mouse
(CMVCre;CHD7+/fl;EZH2+/fl). Calbindin stainings of Control, CHARGE
and reCHARGE mouse cerebellum were used to analyze the cell distribu-
tion of the Purkinje cell layer (Fig. 26A to C).
The cell bodies of neighboring purkinje cells were counted considering
two and three neighboring cells as normal, and thus displaying only
three or more neighboring cells. The values measured for the reCHARGE
condition corresponded to the values measured for the Control litter mates
(Fig. 26D).
Further, the purkinje cell body size was quantified by measuring
Calbindin stained cells. In comparison to the cell sizes quantified for the
Control animals, CHARGE purkinje cells were not significantly smaller.
However, the cell size of purkinje cells grown under reCHARGE condi-
tions were significantly bigger than the cell bodies quantified for CHARGE
mice (Fig. 26E).
Corresponding to the results obtained in CHARGE mouse cerebel-
lum, visible primary branches of purkinje cells were quantified. The
significantly reduced amount of purkinje cells with a primary branch
found in CHARGE mouse were not visible in the reCHARGE mouse.
The amount of purkinje cells with a visible primary branch of the het-
erozygous double knock-out corresponded to the Control values (Fig. 26F).
2.2 The reCHARGE Mouse 56
Figure 25: reCHARGE cerebellum displays no anterior lobe de-
fect A, D and G: Photograph of the brain of ten week old Con-
trol (CMV Cre-), CHARGE (CMVCre;CHD7+/fl) and reCHARGE
(CMVCre;CHD7+/fl;EZH2+/fl) mouse. Brains were placed next to a scale
directly after dissection. B, E and H: Zoomed picture of the cerebellum
marked at V and VI lobe. The scale is indicated on the right [mm]. C, F
and I: Nissl staining of the medial cerebellum. Roman numbers indicate
the lobi. Ant = anterior, pos = posterior.
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Figure 26: reCHARGE purkinje cell layer is unremarkable. The ten
week old Control (CMV Cre-), CHARGE (CMVCre;CHD7+/fl) A to C:
Stained brain slices of the ten week old Control (CMV Cre-) and CHARGE
(CMVCre;CHD7+/fl) mice cerebellum were stained for Calbindin and
DAPI, pictures were taken with a confocal microscope LSM780 (Zeiss).
D: Neighboring cells of each purkinje cell were measured; n=347 Con-
trol and n=408 CHARGE mouse cells, p=0.0107 Control vs. CHARGE,
Control vs reCHARGE n.s. E: Quantification of Purkinje cell-body size
in Control and CHARGE mouse. Cell-body sizes were measured using
a scale tool of ImageJ; n=33 Control and 37 CHARGE mouse cells, Control
vs. CHARGE n.s., Control vs reCHARGE n.s. F: Purkinje cells with visi-
ble primary branches were manually quantified; n=141 Control and n=230
CHARGE mouse cells. N-values represent cell numbers counted from dif-
ferent brain slices. Control Purkinje cells n=392, CHARGE purkinje cells
n=779, reCHARGE purkinje cells n=324, of three animals per genotype,
p=0.0344 Control vs. CHARGE, Control vs. reCHARGE n.s. Several stain-
ings of three mice per genotype were quantified. Statistics were done with
a students t-test.
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Figure 27: reCHARGE purkinje cells have a EZH2 signal A to
C: Stained cerebellum brain slices of Control (CMV Cre-), CHARGE
(CMVCre;CHD7+/fl) and reCHARGE (CMVCre;CHD7+/fl;EZH2+/fl)
mice were stained for Calbindin, EZH2 and DAPI. Z-stacks were taken
with an 100x objective of a laser microscope (LSM780, Zeiss).
The EZH2 expression of purkinje cells was likewise analyzed in the
reCHARGE mouse. The EZH2 signal is visible in the purkinje cell nucleus
(Fig. 27A to C).
2.2.3 Neural Stem Cells in CHARGE vs reCharge Mouse DG
Pervious data showed already a reduction of BrdU and nestin positive
cells in the CHARGE mouse dentate gyrus. Thus, these markers were also
investigated in the reCHARGE mouse dentate gyrus.
BrdU and Nestin positive cells were analyzed after 5 consecutive days
of BrdU treatment. Control (CMV Cre-), CHARGE (CMVCre;CHD7+/fl)
and reCHARGE mouse (CMVCre;CHD7+/fl;EZH2+/fl) were stained for
BrdU and Nestin (Fig. 28 A to C and zoomed pictures D to F). BrdU and
Nestin positive cells were quantified together. A reduction of BrdU and
nestin positive cells could be observed in the CHARGE dentate gyrus,
while the amount of BrdU and nestin positive cells quantified in the
reCHARGE dentate gyrus correlated to values measured for the Control
litter mates (Fig. 28G).
2.3 Summary of CHARGE and reCHARGE Mouse
A novel CHARGE mouse line (CMVCre;CHD7+/fl) was generated, and an-
alyzed. The olfactory lobes were smaller and expressed less doublecortin,
a marker for newborn neurons. CHARGE mice weight significantly less
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Figure 28: reCHARGE mice display no stem and label retaining cell de-
fect The ten week old Control (CMV Cre-), CHARGE (CMVCre;CHD7+/fl)
and reCHARGE (CMVCre;CHD7+/fl;EZH2+/fl) mice were treated with
BrdU for 5 days and dentate gyrus were stained. A to C: Immunoflu-
orescence picture of BrdU, Nestin and DAPI in Control, CHARGE and
reCHARGE dentate gyrus (overlay). Pictures were taken using a confocal
laser microscope (LSM780, Zeiss). D to F: Zoom-in pictures showing cells
with BrdU and Nestin overlay signal (white arrow). G: Double positive
cells were counted manually for each mouse genotype; n=7 Control, n=3
CHARGE and n=3 reCHARGE animals, p=0.0326 Control vs. CHARGE,
Control vs. reCHARGE n.s. Four brain slices were count per animal. Statis-
tics were done with a students t-test.
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than their Control litter mates, and the most severely affected CHARGE
mice had a reduced brain-to-body ratio.
An open field test revealed that CHARGE mice run faster and travel
further.
Besides that, the eye phenotype of CHARGE mice showed a hetero-
geneity between the left and the right eye. Ranging from only rudimentary
developed to smaller eyes, the variation within the CHARGE group was
quite high. The data showed that less severe affected eyes grown under
CHARGE conditions are smaller and have a reduced retina thickness. An
analysis of the retina cell layers revealed that the inner nuclear cell layer
was thinner in CHARGE mice retinas, than the retinas quantified of their
Control litter mates.
The anterior lobe of the cerebellum was underdeveloped under
CHARGE conditions and the purkinje cell layer was disrupted. Purkinje
cells were measured with regard to their number of neighboring cells, cell
body size and the mount of cells with visible primary branches. In the
CHARGE cerebellum over 25% of the cells had three or more neighboring
cells, while the Control displayed less than 5% of cells with more than
three neighboring cells. Also, the amount of purkinje cells with a visible
primary branch were significantly reduced in CHARGE mice compared to
Control litter mates.
Another small analysis revealed an EZH2 expression in the nucleus
of purkinje cells while the protein level of EZH2 and H3K27me3 was not
changed in the CHARGE mouse cerebellum.
A genetic rescue of the CHARGE mouse (CMVCre;CHD7+/fl) was
generated (CMVCre;CHD7+/fl;EZH2+/fl) and analyzed. This heterozy-
gous double knock-out was confirmed via qPCR, and illustrated by
stainings. Mice carrying both heterozygous mutations of chd7 and ezh2
showed no alterations in body weight, or brain-to-body ratio. The eyes
were unremarkable even though an analysis revealed that the overall eye
size was still smaller than measured Control values. Unlike the CHARGE
retina the reCHARGE retina thickness corresponded to the Control values.
H & E stainings of the reCHARGE retina revealed a wavy structure
and unlike the CHARGE mouse retina no retina layer was significantly
altered in comparison to retina layers measured for Control litter mates.
Furthermore, the ectopic MASH1 expression of the CHARGE mouse retina
could not be observed in the reCHARGE mouse retina.
Under reCHARGE conditions no structural damage of the cerebella
anterior lobe could be found. Purkinje cells were bigger than CHARGE
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purkinje cell bodies, but still within an average range measured for
Control mice. Unlike the CHARGE mouse cerebellum, purkinje cells of
the reCHARGE cerebellum had three or more neighboring cells as often
as they were counted in the Control litter mates, and purkinje cells with
primary branches were quantified as often as they were quantified under
wildtype conditions.
A RNA sequencing of the cerebellum tissue of Control, CHARGE
and reCHARGE mice showed striking similarities between Control and
reCHARGE litter mates. Especially, some under CHARGE conditions
downregulated genes were rescued efficiently in reCHARGE mice.
Furthermore, neural stem cells of the dentate gyrus grown under
reCHARGE conditions showed no significant difference in correlation to
cells quantified for Control mice (BrdU and nestin positive cells).
Taken together, the reCHARGE condition represents a partial rescue of
the CHARGE mouse phenotype.
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2.4 Inducible homozygous Knock-out of chd7 and ezh2
A previous study reported that neural stem cells were altered un-
der CHD7 deficiency. A homozygous, inducible chd7 knock-out
(NesCreERT2;CHD7fl/fl) displayed a decreased amount of stem and
label retaining cells (BrdU) in the dentate gyrus. These mice displayed
furthermore more cell proliferation (Ki67) in the subgranular zone of the
dentate gyrus (Feng, W. et al. 2013).
Since the results obtained for the reCHARGE mouse dentate gyrus
stem cells showed a rescue, cells carrying a chd7 and ezh2 knock-out were
further investigated. A nestin promoter was coupled to an inducible Cre
recombinase to enable a time dependent homozygous knock-out in the
neural stem cells of the adult dentate gyrus. An unconditional homozy-
gous knock-out of either chd7 or ezh2 alone is lethal, thus both floxed genes
were coupled to an inducible nestin promotor, using the ERT2 system
(NesCreERT2). which made the stem cell knock-out inducible by the injec-
tion with Tamoxifen. A homozygous double knock-out of chd7 and ezh2
was generated (NesCreERT2;CHD7fl/fl;EZH2fl/fl, interchangeably called
double knock-out), analyzed and the results are presented in the following.
2.4.1 The double Knock-out has no Defect in Stem and Label-Retaining
Cells of the Dentate Gyrus
As a marker for stem cells, and the promotor guiding the knock-out of
chd7 and ezh2 in the homozygous double knock-out, the amount of nestin
expressing cells were analyzed (Fig. 29).
The ten week old mice were injected on five following days with ta-
moxifen to induce the knock-out, and after another two, four or six weeks
respectively the mice were sacrificed (Fig. 29A). The hippocampal dentate
gyrus was analyzed (Fig. 29B). Control (NesCre-) and double knock-out
(NesCreERT2;CHD7fl/fl;EZH2fl/fl) dentate gyrus were stained for nestin
(Fig. 32C and D). The nestin positive cells were manually counted in a
blind study. Two weeks after the knock-out induction with tamoxifen, the
double knock-out had significantly less nestin positive cells. After four and
six weeks however, the amount of nestin positive cells was not significantly
different to the amount of nestin positive cells counted for the Control litter
mates (Fig. 32E).
To further investigate the stem cells in the double knock-out
(NesCreERT2;CHD7fl/fl;EZH2fl/fl), cells were labeled with BrdU and ana-
lyzed according to a previous study. In this study a NesCreERT2;CHD7fl/fl
mouse line displayed a defect in the BrdU positive cells. Interestingly, this
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Figure 29: The amount of nestin positive cells in the double knock-out
corresponds to Control values. A: The ten week old Control (NesCre-
) and double knock-out (NesCreERT2;CHD7fl/fl;EZH2fl/fl) were treated
with Tamoxifen for 5 days and after another two to six weeks sacrificed,
brains were stained. B: A scheme of the coronally cut mouse brain show-
ing the dentate gyrus. C and D: Example histology pictures stained with
Nestin. E: The quantification of nestin positive cells was done manually
and 4 to 6 dentate gyrus pictures were count per animal. The time points
2 weeks, 4 weeks and 6 weeks indicate the time after the knock-out induc-
tion; n=5 at two weeks, n=5 at four weeks, n=7 at 6 weeks were analyzed
for the Control mouse line, and n=4 at two weeks, n=5 at four weeks, n=12
at six weeks were analyzed for the double knock-out. P=0.033 Control vs.
double knock-out, two weeks after knock-out induction, other time points
n.s. Four brain sections were counted per mouse. Statistical analysis t-test
(sigma plot). Statistics were done with a students t-test.
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defect could be overcome through voluntary running (Feng et al., 2013).
In brief, the 10 week old mice (NesCreERT2;CHD7fl/fl;EZH2fl/fl) were
injected 5 consecutive days with tamoxifen. After another two weeks, the
mice were placed into a running cages and injected with BrdU for twelve
days. The following three weeks the running experiment continued after
which the mice were sacrificed (Fig. 30A). The hippocampal dentate gyrus
was stained and analyzed (Fig. 30B). Z-stacks were taken and the BrdU
positive cells in the granular layer were manually counted in a blind study
(Fig. 30C to J).
Regarding the amount of BrdU positive cells, a difference could be
seen only in running vs. non-running animals. Unlike the chd7 single
knock-out, the double knock-out did not show any significant difference
in the amount of neural stem cells between Control and mutant mice (Fig.
30K).
In this context, the position of the BrdU labeled neural stem cells was
analyzed. Dividing the granular layer of the dentate gyrus into subgran-
ular layer, middle and upper granular layer the distribution of cells was
analyzed, but no significant change could be observed (supplement data
Fig. 57).
Taken together, the analyzed stem cells expressing nestin and cells
labeled with BrdU showed no difference between the Control and the
double knock-out (NesCreERT2;CHD7fl/fl;EZH2fl/fl).
2.4.2 The double Knock-out has no Proliferation Defect in the Dentate
Gyrus
A previous study showed an increased proliferation in the granular zone
of the dentate gyrus in a NesCreERT2;CHD7fl/fl mouse line (Feng et al.,
2013, supplement Fig. 45). Therefore, the proliferation of the homozygous
double knock-out (NesCreERT2;CHD7fl/fl;EZH2fl/fl) was tested under
comparable conditions.
A proliferation marker used in this study was Ki67. This marker
overlays with bot CHD7 and EZH2 in the nucleus of neural stem cells (Fig.
31A to J).
For this analysis 10 week old mice were injected with tamoxifen on 5
constitutive days. After another six weeks the mice were analyzed (Fig.
31K). The hippocampal dentate gyrus was stained for Ki67, and the
positive cells were count manually in a blind study (Fig. 31L, M and N).
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Figure 30: The amount of BrdU labeled cells in the double knock-
out corresponds to Control values. A: Timing of the running ex-
periment. The ten week old Control (NesCre-) and double knock-out
(NesCreERT2;CHD7fl/fl;EZH2fl/fl) mice were treated for 5 days with ta-
moxifen and began after two more weeks the running experiment in which
they were treated with BrdU for twelve days and sacrificed after 4 weeks
in running cages. B: A scheme of the coronally cut mouse brain showing
the dentate gyrus. C to J: Section of the dentate gyrus were stained with
NeuN and BrdU. D: The quantification of BrdU positive cells was done
manually and 4 to 6 dentate gyrus pictures were count per animal; n=5
Control mice, n=6 double knock-out mice, n=5 Control mice in running ex-
periment, and n=7 double knock-out mice were analyzed in the running
experiment. P=0.044 between Control group and Control group in running
Control group. Statistics were done with a students t-test.
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The Ki67 positive cells showed in contrast to the single knock-out of
chd7 no difference between Control and double knock-out (Fig. 31O).
2.4.3 The double Knock-out displays a normal Amount of Newborn
Neurons in the Dentate Gyrus
Previous data suggested that an ezh2 knock-out (NesCreERT2;EZH2fl/fl)
might affect the number and positioning of immature neurons (data shown
in supplement Fig. 44, doublecortin, MCM2, Li, Y.). The homozygous ezh2
mutant started with more new-born neurons (Doublecortin) than their
Control litter mates 2 weeks after the knock-out induction, and showed
less new-born neurons after 12 weeks.
This observation suggested an analysis of doublecortin positive cells in
the double knock-out (NesCreERT2;CHD7fl/fl;EZH2fl/fl). For this study,
ten week old mice were treated with Tamoxifen to induce the knock-out
and analyzed 2 to 6 weeks later (Fig. 32A).
Coronal brain sections of the hippocampal dentate gyrus were histo-
logically stained and analyzed (Fig. 32B, C and D).
In a blind analysis, the doublecortin positive cells were counted
manually. Only two weeks after the induction of the double knock-out,
the amount of doublecortin positive cells was measured higher in the
Control animals. At later time points the difference was not significant.
The amount of new-born neurons of the double knock-out mice never
exceeded the cell numbers measured under Control conditions. Both cell
populations decrease equally over time (Fig. 32E).
Because of the seemingly altered distribution of doublecortin cells in
the ezh2 single knock-out (supplement Fig. 44), the cell distribution of
newborn neurons was also analyzed for the double knock-out of chd7
and ezh2 (NesCreERT2;CHD7fl/fl;EZH2fl/fl). Furthermore, the dendritic
length and the orientation of doublecortin positive cells in the dentate
gyrus was measured, but none of the analyzed parameters were signif-
icantly changed in the double knock-out compared to the cells grown
under Control conditions (Fig. 58, 59, 60, 61 in the supplement).
Similar to the doublecortin phenotype a single knock-out of ezh2
(NesCreERT2;EZH2fl/fl) seemed to posses first more and then less MCM2
positive cells than the Control mice (supplement Fig. 44, NestinCreERT2
EZH2fl/fl, Li, Y.). Two and four weeks after the knock-out induction new-
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Figure 31: The double knock-out shows no increase in proliferation Con-
trol (NesCre-) and double knock-out (NesCreERT2;CHD7fl/fl;EZH2fl/fl).
A to J: Neural stem cells stained with Ki67, DAPI and either CHD7 or
EZH2. K: Timing of the running experiment. The ten week old mice were
treated for 5 days with tamoxifen and were sacrificed six weeks later. L:
A scheme of the coronally cut mouse brain showing the dentate gyrus. M
and N: Example histology stainings of Ki67 in Control and double knock-
out mice. O: Manual quantification of the Ki67 positive cells in the den-
tate gyrus; n=11 mice per genotype, four brain sections were counted per
mouse (n.s.). Statistics were done with a students t-test.
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Figure 32: The amount of newborn neurons correlates
with the amount measure in Control mice (NesCre- and
NesCreERT2;CHD7fl/fl;EZH2fl/fl). A: The ten week old litter mates
were treated with Tamoxifen for 5 days and after another two to six
weeks sacrificed, and stained. B: A scheme of the coronally cut mouse
brain showing the dentate gyrus. C and D: Slices of the dentate gyrus
were stained histologically for doublecortin. E: The quantification of
doublecortin positive cells was done manually and 4 to 6 dentate gyrus
pictures were count per animal. The time points 2 weeks, 4 weeks and 6
weeks indicate the time after the knock-out induction. Animal numbers
are mentioned as n-values: n=6 at 2 weeks, n=8 at 4 weeks, n=9 at 6 weeks
were analyzed for the Control mouse line, and n=5 at 2 weeks, n=3 at 4
weeks, n=11 at 6 weeks were analyzed for the double knock-out mouse
line. P=0.0096 Control vs. Mutant two weeks after knock-out induction.
Other time points n.s. Statistics were done with a students t-test.
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born neurons expressing MCM2 were first higher in the homozygous ezh2
knock-out and then lower 8 weeks and 12 weeks after the induction.
Thus, the amount of MCM2 positive cells were quantified in the double
knock-out (NesCreERT2;CHD7fl/fl;EZH2fl/fl). The ten week old mice
were treated with tamoxifen and sacrificed after one to six weeks (Fig. 33,
A).
Coronal brain slices of the hippocampal dentate gyrus were stained for
MCM2 and positive cells were counted manually (Fig. 33B, C and D).
Two weeks after the knock-out induction with tamoxifen the Control
mice displayed significantly more MCM2 positive cells. Similarly four
weeks after the tamoxifen injections the Control mice showed more MCM2
positive cells. However, this difference was not visible six weeks after the
knock-out induction. In the homozygous double knock-out the amount of
MCM2 positive cells never exceeded the amount measured in the Control
mice (Fig. 33, graph C).
2.5 Summary of the inducible chd7 and ezh2 Knock-out
The amount of nestin positive cells in the dentate gyrus of the double
knock-out (NesCreERT2;CHD7fl/fl;EZH2fl/fl) was less two weeks after
the knock-out induction, while it normalized four and six weeks after the
induction to a non-significant amount, in comparison to the Control litter
mates (NesCre-). Likewise the amount of BrdU positive cells in a running
experiment analyzed in total six weeks after the knock-out induction, was
not significantly different from their Control litter mates.
The amount of Ki67 positive cells, a marker for proliferation was in
contrast to a chd7 single knock-out also not altered, in total six weeks after
the knock-out induction.
Cells positive for doublecortin and MCM2, two markers for newborn
neurons displayed a significant reduction only two weeks after the knock-
out induction while the amount of positive cells normalized six weeks
after the tamoxifen injections.
Taken together, the double knock-out showed significantly less nestin,
doublecortin and MCM2 positive cells two weeks after the knock-out
induction while the amount of nestin, doublecortin, MCM2, Ki67 and
BrdU positive cells showed no difference between the Control and the
double knock-out six weeks after the knock-out induction.
These results show that important differences which were observed in
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Figure 33: The amount of early newborn neurons correlates with the
amount measure in Control mice Control (NesCre-) and double knock-
out (NesCreERT2;CHD7fl/fl;EZH2fl/fl) A: The ten week old litter mates
were treated with Tamoxifen for 5 days and after another two to six weeks
sacrificed. B: A scheme of the coronally cut mouse brain showing the den-
tate gyrus. C and D: Slices of the dentate gyrus were histologically stained
for MCM2. E: The quantification of MCM2 positive cells was done man-
ually and 4 to 6 dentate gyrus pictures were count per animal. The time
points 2 weeks, 4 weeks and 6 weeks indicate the time after the knock-out
induction: n=5 at 2 weeks, n=5 at 4 weeks, n=6 at 6 weeks were analyzed
for the Control mouse line, and n=6 at 2 weeks, n=4 at 4 weeks, n=12 at 6
weeks were analyzed for the double knock-out mouse line. Animal num-
bers are mentioned as n-values. P=0.0065 Control vs. Mutant two weeks
after knock-out induction. Other time points n.s. Statistics were done with
a students t-test.
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the dentate gyrus stem cell population of a single knock-out of either chd7
or ezh2, were not observed in the homozygous double knock-out of chd7
and ezh2 together. In contrast to the chd7 single knock-out neither BrdU
nor Ki67 were different in the double knock-out compared to the littermate
Control mice. Also, a difference in the ezh2 single knock-out namely the
MCM2 and doublecortin positive cells shifting from more positive cells in
the ezh2 single knock-out to less cells over time, could not be observed in
the double knock-out mice. The amount of new-born neurons was always
less in the double knock-out than measured in the Control litter mates and
normalized over time.
2.6 Treatment with the EZH2 Inhibitor GSK126
All the herein presented data supported the idea that EZH2 activity
reduction could be beneficial for the CHARGE phenotype. This concept
could in theory be extended to a novel treatment of CHARGE neural stem
cells by inhibiting EZH2 activity. This is especially attractive because
EZH2 can be inhibited with a very potent and selective inhibitor called
GSK126, which is already tested in clinical trails as cancer treatment.
The question arose whether this inhibitor was potent in cells and in
vivo, and if it could be used on neural stem cells with a CHD7 knock-down.
Beyond that, could this non-permeable drug be a administered to the brain.
2.6.1 In vitro - CHD7 Knock-down Cells tolerate a Treatment with the
EZH2 Inhibitor
The EZH2 inhibitor GSK126 is already part of several clinical anti-cancer
trails and hence a major cytotoxic effect was not expected. It was de-
termined how cells with a CHD7 knock-down reacted to an additional
inhibitor treatment, and the resulting downregulation of EZH2 in vitro.
Thus, HEK293T cells with and without CHD7 knock-down were tested
in combination with the EZH2 inhibitor GSK126. These knock-down
cells were generated, sequenced and provided by W. Feng. The CHD7
knock-down could be confirmed via qPCR, and also the EZH2 expression
was tested, but found to be unremarkable (Fig. 34A and B).
Next these cells were seeded with a density of 100.000 cells per dish,
and incubated with either 0, 1 or 2 µM GSK126. After 72 h of incubation
the cells were growing by optical means rather normal (Fig. 34C).
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Figure 34: The EZH2 inhibitor GSK126 is capable of sufficient H3K27me3
downregulation on CHD7 knock-down cells. A and B: The RNA of
HEK293T cells with CHD7 knock-down (provided by W. Feng) was iso-
lated, the cDNA was prepared an a cybergreen qPCR for CHD7, EZH2 was
run. C: HEK293T cells with a CHD7 knock-down were incubated with 0,
1 or 2 µM of the EZH2 inhibitor GSK126. Pictures were taken after 72 h
incubation. D: Western blot for H3K27me3 (17 kDa) using the harvested
HEK293T cells with chd7 knock-down after 72 h of GSK126 incubation.
After the treatment with the EZH2 inhibitor, the cells were tested for
a H3K27me3 reduction, since this would indicate a EZH2 inhibition. For
both 1 and 2 µM a reduction of H3K273 could be observed (Fig. 34D).
Thus, CHD7 knock-down cells tolerate the EZH2 inhibitor and the
inhibitor is sufficient for the downregulation of histone mark H3K27me3.
Here the results of the in vitro tests motivated a further in vivo analysis
of the EZH2 inhibitor GSK126.
2.6.2 In vivo - the EZH2 Inhibitor can be Administered to the Brain an
reduces H3K27me3 Protein Level
As mentioned before the EZH2 inhibitor GSK126 does not cross the
blood-brain-barrier which excludes the possibility of an IV injection to
treat neural stem cells or the brain. Hence another approach needed to be
tested. To gain a constant infusion of the dentate gyrus stem cells with the
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EZH2 inhibitor GSK126, an osmotic pump was surgically installed.
Used were eight week old NesCreERT2 CHD7fl/fl animals, and the
knock-out was induced by 5 days of subsequent Tamoxifen injections. Af-
ter four weeks the pump surgery was performed with Cre positive and Cre
negative litter mates. Of both genotypes half of the animals got the EZH2
inhibitor and CldU and the other half got only CldU in physiological NaCl
solution. The infusion took place over a period of 5 days and after another
two days the mice got a single IdU or BrdU injection and were sacrificed
(Fig. 35A).
The osmotic pump was fixed to the hippocampal dentate gyrus to target
neural stem cells carrying a chd7 knock-out with the EZH2 inhibitor (Fig.
35B).
A surgery procedure could be established in a way that seven mice
survived the treatment. Unfortunately all of them were Control mice.
Nevertheless, the cut and stained left (not treated e.g. without GSK126)
and right dentate gyrus (treated with GSK126 and CldU) of these Control
mice could be analyzed after the treatment with the osmotic pump.
The inhibitor was infused together with CldU and the pictures show a
CldU signal only on the infused brain site (e.g. this site of the brain was
connected to the pump). This suggests that the left dentate gyrus had no
contact with the pump fluid through the thick brain tissue (Fig. 35C to H).
After the surgery the brain tissue of four mice was dissected, covering
a narrow square of 2x2 mm around the pump infusion site and a respective
square of the non-infused brain site as Control. Two of them were treated
with the EZH2 inhibitor GSK126 (mouse 2 and 4), the other two were
treated with NaCl (mouse 1 and 3). The tissue was prepared for western
blot and blotted for H3K27me3. Here the tissue of the right dentate gyrus
(treated) showed a weaker H3K27me3 level than the left dentate gyrus
(not treated) of the same mouse indicating a working treatment with the
EZH2 inhibitor GSK126 on the brain tissue of two mice (Fig. 35I).
This experiment shows that it is possible to treat the brain with the
EZH2 inhibitor GSK126 in vivo, and that the medical infusion could be
limited to at least one brain hemisphere.
2.7 Summary of a Treatment with the EZH2 Inhibitor GSK126
The EZH2 inhibitor GSK126 could sufficiently inhibit the EZH2 activity in
CHD7 knock-down cells.
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Figure 35: The EZH2 inhibitor infusion is capable of reducing the
H3K27me3 in vivo A: Eight week old NesCreERT2;CHD7fl/fl mice were
treated with tamoxifen for five consecutive days to induce the knock-out.
After another four weeks the osmotic pump was placed by surgery and in-
fused for five days constantly either GSK126 and CldU, or NaCl and CldU
to Control and knock-out mice each. Bevor harvesting the mice, a single
BrdU injection was given 2 hours before sacrificing the mice. B: Coronal
brain section, the hippocampal dentate gyrus was targeted. C to H: The left
and right dentate gyrus of the same animal was stained for CldU and DAPI.
I: The tissue of the dentate gyrus was collected after the pump surgery in-
fusion time, in a narrow square of 2x2 mm around the infusion site and
non-infused brain site as a Control. The mice were infused with the EZH2
inhibitor GSK126 on the right site of the brain, while the left hemisphere
remained untreated (-GSK and +GSK). Tissue of the left and right dentate
gyrus of four mice was blotted agains H3K27me3 and beta-tubulin.
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Different chemically altered versions of this Inhibitor were tested on
HEK293T cells to determine the working concentration and on neural stem
cells to analyze the efficient EZH2 inhibition by blotting H3K27me3.
A pump surgery procedure could be established and the treatment
was sufficient to show a reduced H3K27me3 level in the brain tissue. The
results suggested that the infused fluid does not reach the complete brain
but is rather limited to a small area of the brain.
2.8 RNA Sequencing of CHD7+/fl and CHD7+/flEZH2+/fl Cere-
bellum Tissue
To further analyze the molecular alterations in the gene expression of
CHD7 deficient brain tissue and tissue expressing genes under CHD7 and
EZH2 loss, a RNA sequencing was performed. For this experiment the
RNA expression of CMVCre;CHD7+/fl and CMVCre;CHD7+/flEZH2+/fl
mice were compared to each other and to their control litter mates. Thus,
the effect of a heterozygous CHD7 or heterozygous CHD7 and EZH2
expression on the RNA level of other genes in the cerebellum tissue was
analyzed respectively.
For the RNA sequencing one half of the cerebellum was prepared
and the RNA was isolated. The relative CHD7 and EZH2 expression of
Control, CHARGE and reCHARGE mice cerebellum was tested by qPCR
before the sequencing was performed and showed a downregulation
of CHD7 for CHARGE and a downregulation of CHD7 and EZH2 for
reCHARGE mice in comparison to the Control litter mates (Fig. 36A and B).
The RNA of the cerebellum tissue (which was previously analyzed
by qPCR) was analyzed by RNA sequencing. The resulting data of
significantly changed genes show diffenences between the mouse groups
(Control, CHARGE and reCHARGE) which are depicted as heat map. The
data indicates a clear difference between CHARGE and Control mice. The
profiles of two reCHARGE mice seems similar to the control mice profile,
while animal reChareg2 showed a heterogenouse gene expression (Fig.
36C).
Significantly downregulated processes of CHARGE vs. Control mice
were analyzed and are shown as Processes and Benjamini p-values. In
the context of the chd7 knock out, especially long term memory, mRNA
processing and regulation of neuronal plasticity seem remarkable (Fig.
36D).
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In granular neuron progenitor cells of the cerebellum which carried
a chd7 knock-out (Fig. 46 from Feng et al., 2017, supplement), regulatory
processes of neuronal plasticity were likewise affected. Further, the process
of learning and memory was affected in granular neurons while a related
process namely long term memory was significantly downregulated in the
CHARGE tissue. Also, the ion transport was altered in both knock-outs
- ion transport in granular progenitors and potassium ion transmembran
transport under CHARGE condition.
Figure 37: RNA sequencing graphs of significant changed genes in
CHARGE vs. Control and reCHARGE vs. Control This graph was pro-
duced in team work with C. Shao.
The RNA sequencing data was analyzed in regard to the rescued genes
observed for the reCHARGE condition in comparison to the CHARGE
mouse gene expression (Fig. 37 and Fig. 38A). A comaprison the changed
gene expression of core genes showed that under CHARGE conditions 702
genes were altered in relation to control conditions, while 168 genes were
differently regulated in CHARGE versus reCHARGE conditions. Remark-
ably 218 genes were rescued from CHARGE to reCHARGE condition(Fig.
37A)). These altered core genes were either slightly up- or down regulated
(Fig. 37B).
A volcano plot depicts significantly and not significantly changed
genes. Especially intriguing are the depicted genes which are significantly
changed but rescued under reCHARGE conditions in comparison to the
measured CHARGE gene expression. The graph clearly shows that under
reCHARGE conditions some up- and more downregulated genes of the
CHARGE condition, are efficiently rescued (Fig. 38B).
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Figure 36: The RNA profile of CHARGE mouse cerebellum differs to the
expression of Control mouse cerebellum, while reCAHRGE mouse ex-
pression is more similar to the Control mouse expression. The cerebellum
of Control (CMV Cre-), CHARGE (CMVCre;CHD7+/fl) and reCHARGE
(CMVCre;CHD7+/fl;EZH2+/fl) mice were dissected and shock frozen into
liquid nitrogen. A: The RNA of the cerebellum tissue was isolated and
analyzed with qPCR for the CHD7 expression. Values were normalized
to Actin and samples with working standard are shown; n=3 Control,
n=4 CHARGE and n=4 reCHARGE mice, p=0.0096 Control vs. CHARGE,
p=0.0055 Control vs. reCHARGE. C: Three mice per genotype were send
for RNA sequencing. B: The RNA of the cerebellum tissue was isolated and
analyzed with qPCR for the EZH2 expression. Values were normalized to
Actin and samples with working standard are shown; n=3 Control, n=4
CHARGE and n=4 reCHARGE mice, Control vs. CHARGE n.s., p=0.0053
Control vs. reCHARGE. C: Three mice per genotype were send for RNA
sequencing. Resulting heat map of the RNA sequencing showing the sig-
nificantly changed genes for all three genotypes. This graph was produced
by C. Shao. D: Significantly altered cellular processes between CHARGE
mouse and Control are depicted. Statistics were done with a students t-
test.
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Figure 38: reCHARGE rescues certain genes up- and downreg-
ulated under CHARGE conditions. The volcano plot depicts the
log2 fold change of genes of CHARGE and reCHARGE mouse
cerebellum tissue. Efficiently rescued genes are depicted. This
graph was produced by C. Shao.
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3 Discussion
3.1 The CHARGE Mouse
A novel CHARGE mouse could be generated and analyzed.
(CMVCre;CHD7+/fl). Due to the CMV promotor which is capable of
knocking-out genes already in the germ line and thus maybe deleting the
floxed genes in planed future Control mice, only CMVCre and CHD7fl/fl
mice were crossed.
The CHARGE mouse olfactory bulbs were smaller and structural dif-
ferent to the olfactory bulbs of their Control litter mates. Less doublecortin
was expressed in this CHD7 deficient tissue, which corresponded to a pre-
vious analysis were less BrdU and doublecortin positive cells were found
under CHD7 deficiency (Feng et al., 2013). A decreased amount of new-
born neurons may claim a share in the poor olfactory bulb overall structure.
Since CHARGE syndrome results in a smaller body size, a total of 29
mice were weighed (Fig. 9). The adult male and female mice weighed
significantly less than their Control litter mates. The brain-to-body ratio
was in general not affected, only three severely affected mice displayed
significantly reduced brain weights.
Already with these few experiments a variation in the phenotype of the
CMVCre;CHD7+/fl mice was visible.
A high symptomatic variation has also been reported for human
CHARGE patients and CHARGE syndrome has been described as a very
heterogene disease consisting of several clinical features. One study
analyzed CHARGE family cases and found a wide clinical variability
(Jongmans et al., 2008). Furthermore, symptoms of CHARGE syndrome
overly with other syndromes like Kubiki-syndrome (Schulz et al., 2014).
And a inappropriate p53 activation during the development reassembled
CHARGE features (van Nostrand et al., 2014). It was argued that the
presence of genetic modifiers, the type of mutation in chd7 as well as
interactions with the environment could explain the difference in the
phenotypic expression of CHARGE patients (Bosmann et al., 2005).
However, in mice bearing the same chd7 mutation, having the same
genetic background and experiencing the same surrounding, some of these
variables can be excluded. The CMV promotor is active during embryonic
development, but it is not fully understood at which embryonic day the
knock-out happens. Already small differences in the knock-out induction
can cause a difference in the later developing structures, may causing the
observed variety in the symptoms.
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Further, the CHARGE mice were easily distinguishable from the
Control litter mates due to their striking behavior. Videos were recorded
showing head shaking movements, tremble moving patterns and fast
circle running. The so-called ’head bobbling’ has been described before
(Bosman et al., 2005) and also a hyperactive phenotype of CHARGE mice
was reported (Ogier et al., 2014). To evaluate how fast the CHARGE mice
were moving, an open field test was conducted. The resulting videos were
analyzed by using ImageJ macros and showed a clear difference between
Control and CHARGE mutant mice (Fig. 10).
These recorded moving patterns in the open field suggest that the
CHD7 deficient mice do not avoid the center of the open field as much as
the Control mice do, which might indicate a less fearful behavior (open
field figure 10A and B). CHARGE mice run faster and travel farther than
their Control litter mates (Fig. 10C and D).
However, the experiments were conducted in a mouse housing room,
not excluding the vocalization of other mice which were not tested at
the same time. The open field cage was sterilized after each mouse to
eliminate the smell of other mice. For a professional open field experiment
it is agreed that the experimenter should leave the room or at least hide
behind a curtain to exclude a possible reaction of the running mice to the
presence of the experimenter. Irrespective of these technical problems
(which were the same for all mice tested), the obtained data shows a
significant difference between CHARGE mouse and the Control litter
mates.
Another bias of the behavior studies was the influence of blindness and
a possible impaired inner ear in CHARGE mouse, which the Control mice
do not recapitulate. Especially the ear malformations are intensively inves-
tigated in CHARGE and CHARGE-like mice (Bosman et al., 2005; Ogier et
al., 2014; Ogier et al., 2018). A problem in the inner ear and the equilibrium
sense could quite likely influence the stereotypic head-shake movements
and maybe even the circle running. The here analyzed CHARGE mice
could recapitulate the ear malformations described for CHARGE patients.
However, the inner ear was not investigated in these mice.
For future behavior projects, it would be crucial to exclude blindness
and deafness as influencing the overall behavior.
Experiments evaluating functional vision and auditory sense (not
including any technical devices) are described as jumping from a defined
hight (visuality) and fear reaction to loud noises. Both tests are unfortu-
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nately quite restricted and seem not very reliable thus non of these tests
was conducted.
Nevertheless, the hyperactive circling behavior phenotype of the
CHARGE mice was already obvious in the home cage, and a similar
observation was made in the so called looper mouse (Ogier et al., 2014).
It has been discussed for a long time which brain regions are involved
in hyperactivity. The cerebellum is one of the regions thought to be
involved in hyperactivity, as it gives important movement feedback to
the rest of the brain. Since Purkinje cells give the inhibitory cerebellar
output and are also the only output to the rest of the brain, a different cell
structure, cell amount or activity of the Purkinje cells could potentially
influence the behavior and were indeed found to be altered in the analyzed
CHARGE mouse. However, other brain regions which are thought to be
involved in hyperactive behavior were not analyzed in the CHARGE mice.
The cerebella purkinje cell layer was unremarkable in the genetic rescue
of the CHARGE mouse, the reCHARGE mouse. It would be interesting to
analysis the reCHARGE mouse in regard to their behavior.
For human patients, hyperactivity and autistic behavior trades were
also symptoms of the CHARGE syndrome (Graham et al., 2005; Prancke-
niene et al., 2019), but other studies emphasize that sleep difficulties (59%),
aggressive behavior (51%), tactile defensiveness (51%) and obsessive
compulsive behavior (49%) are more common. In the study by Hartshorne
et al. attention deficits and the autistic spectrum were reported for 26%
of the patients (Hartshorne et al., 2016). Doubtless only some of these
behaviors can be monitored in a mouse model. But the sleep circle and a
possible aggressive behavior of CHARGE mice would be an interesting
point, since this has not been evaluated in CHD7 deficient mice up to now.
3.1.1 Eye Defect in CHARGE Mouse
In 77% to 90% of the human CHARGE patients coloboma of the eye due to
a failure of the optic or choroid fissure to close during fetal development,
resulting in visual impairments up to complete blindness, are reported
(Hartshorne et al. 2016). Surprisingly a mouse model repeating the variety
of eye malformations observed in human patients was missing. Only a
few isolated malformations have been reported like lid oedema, narrow
palpebral fissures and eye nerve hypoplasia (Ogier et al., 2014), cataracts
and dry eye conditions (Bosmann et al., 2005).
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The eye phenotype of the CHARGE mouse (CMVCre;CHD7+/fl)
described herein was striking. Three eyes had to be excluded from further
analysis because they did not share any structural orientation points.
Furthermore, nine out of 14 CHARGE eyes had a closed lid (narrow
palpebral fissures) suggesting either one-eyed or two-eyed blindness of
the respective animal. Interestingly, the left and the right eye displayed
a symptomatic heterogeneity. Almost half of the mice displaying eye
malformations possessed two differently affected eyes. The right eye was
on average 70% affected while the left eye had in 30% of the mice a closed
eye lid. Similar heterogene eye expression patterns have been reported for
CHARGE patients wherein the right eye was stronger affected (Hartshorne
et al., 2016).
Here it was shown that CHD7 deficiency leads to significantly smaller,
and in some cases deformed eyes (Fig. 12). The retina of CHARGE mouse
eyes was thinner and especially the inner nuclear layer was significantly
decrease under CHD7 deficient conditions (Fig. 13).
Stainings revealed less PAX6 positive cells in the inner nuclear and
ganglion cell layer of the CHARGE mice. Little is known about PAX6 task
in the adult retina (Stanescu-Segal et al., 2017), but during the development
PAX6 is usually responsible for a refined development of retinal progenitor
cells, and under PAX6 deficiency only amacrine interneurons are devel-
oped (Marquardt et al., 2001). A missing cell fate refinement due to less
PAX6 expression could thus lead to a reduced cell variety and maybe even
to cell development defects and maybe to increase cell death. This would
be interesting to investigate further. A lack of PAX6 could hence hint
towards a singular cell development leaving out for example mueller glia,
horizontal or ganglion cells. Noteworthy a Pax6 down-regulation has also
been linked in different animal models to retinal degeneration (Stanescu
et al., 2007; Stanescu-Segal et al., 2017) thus probably participating in the
reduced retina thickness observed under CHARGE conditions. However,
following experiments like qPCRs or western blots would be needed to
further proof a reduced PAX6 expression in the retina and in specific cells.
Also, the ectopic expression of basic helix-loop-helix (MASH1) in
the ganglion cell layer of the CHARGE mouse retina was remarkable.
MASH1 is needed for retina neuron differentiation (Kageyama et al.,
1997) and usually only expressed for a limited time during the retina
development. However, positive cells in the ganglion cell layer hint
towards non-differentiated cells. These cells are unlikely müller glia cells,
which usually reside in the inner nuclear layer of the retina. MASH1 is a
marker for bipolar cells of the inner nuclear layer (Jasoni and Reh, 1996)
but again a positioning in the ganglion cell layer is unusual.
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However, continuative studies are needed to further elucidate why
the inner nuclear layer of the CHARGE retina is thinner and/or contains
less cells. One approach would be a BrdU treatment of retina cells mainly
labeling müller glia cells. Animals with marked retinas were prepared
already, but could not be investigated within the time frame of this project.
Additionally, it would be interesting to isolate the complete retina
to further analyze and culture the cell composition and single cell types
for further analysis. Different approaches would then be possible from
knock-out studies to sorting experiments with labeled cells.
3.1.2 Cerebella Defect in CHARGE Mouse
Prior to this analysis W. Feng observed a missing anterior lobe of the
cerebellum under CHD7 deficient conditions (supplement Fig. 47). Since
the analyzed knock-out was an Atho-1::Cre CHD7fl/fl knock-out limited
to the cerebellum, the question arose whether this observation could be
confirmed in the CHARGE mouse cerebellum. In agreement with these
findings the anterior lobe of the cerebellum in 10 week old CHARGE mice
is underdeveloped, the III lobe is missing (Fig. 16). Since this structure
develops latest of all structures in the cerebellum, it could display a
delayed development in comparison to the cerebellum of the Control mice.
Feng et al. found that CHD7 positive cells are mainly found in the inner
granule layer (IGL) of the cerebellum. He also showed that during the
development PAX6 positive cells (granule neurons and progenitors) are
also positive for CHD7, while SOX2 (Bergmann glia cells) and Calbindin
positive cells (Purkinje cells) show only a weak CHD7 expression. Also,
there were detectably less Ki67 positive cells in the BrdU positive popula-
tion suggesting an inappropriate cell cycle exit of granular progenitor cells
(Feng et al., 2017). Since CHD7 deficiency results in an underdeveloped
state of the cerebellum some of these usually embryonically expressed
markers were analyzed in the adult CHARGE mouse to observe differences
and similarities between a CHD7 knock-out restricted to the cerebellum
and one that is affecting the whole brain.
The mouse cerebellum develops postnatally and within this development
granular cells secret Reelin to Purkinje cells while the Purkinje cells secret
Sonic hedgehog to the granular cells. This mechanism is needed for both
cell types to find their right position in the cerebella structure (Feng et al.,
2017). In agreement with these previous findings the CHARGE mouse
(CMVCre;CHD7+/fl) shows a disrupted Purkinje cell layer.
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In this project it could be quantified that each purkinje cell is build
up by more than three neighboring cells in almost 30% of analyzed cells
under CHARGE conditions (Fig. 17). This disorganization of purkinje cells
under CHD7 deficiency has been reported (Feng et al., 2017; Whittaker et
a., 2017). Additionally, herein it was shown that most Purkinje cells devel-
oped under CHD7 deficiency have significantly less primary branches in
comparison to the Control mice (Fig. 17).
The cell processes are needed to pass along signals and can thus be as-
sessed as elementary for the cell function. As purkinje cells are the primary
inhibitory output of the cerebellum, this is a striking phenotype. Further-
more, a bulk of purkinje cells which were not able to build primary pro-
cesses needed for the integration into the cerebellum tissue, would fit into
the bigger picture.
It has been reported that CHD7 deficient mice lack reelin due to a
closed chromatin state. Reelin is a key factor secreted by granular neurons
to guide purkinje cells into the right position in the cerebellum tissue and it
seems purkinje cells may also need a further signaling to integrate into this
cell layer (Feng et al., 2017). Reelin was also tested in the CHARGE mouse
line but outliner rendered the animal number to low to be significant (Fig.
48).
Interestingly, a structural defect in the cerebella anterior lobe (which
was also reported in Feng et al., 2017) was not observed in the genetic
rescue called reCHARGE mouse (CMV Cre CHD7+/fl EZH2 +/fl). They
were indistinguishable from the Control mice anterior lobe.
3.1.3 Neural stem cells in CHARGE Mouse
The hippocampal dentate gyrus is a brain region involved in learning and
memory. Adult neural stem cells reside in this area and develop eventually
into newborn neurons, which integrate into the subgranular zone. A defect
in these cells may be associated with learning difficulties.
CHARGE mice were less fearful in the open field test and stayed in
the center of the open field without worry, which may hint towards an
impaired (fear-context) learning. Thus, stem and label retaining cells were
marked with BrdU in the CHARGE mouse dentate gyrus to analyze this
cell population.
A quantified staining for BrdU and nestin together revealed less double
positive cells in the dentate gyrus of CHARGE mouse (Fig. 4.2.1). Indi-
cating less stem cells in this region. Possible learning difficulties resulting
3 Discussion 85
from this phenotype would be worth to investigate because of these hints.
3.2 Summary of the CHARGE Mouse Data
The CHARGE mouse (CMVCre;CHD7+/fl) could be generated an dis-
played a variety of symptoms, some of which could be analyzed in this
study. CHARGE mice had smaller olfactory bulbs corresponding to the
human phenotype (Vissers et al., 2004). The olfactory bulbs showed less
doublecortin expression, hinting towards a decreased amount of newborn
neurons.
Mutant CHARGE mice were significantly smaller than their litter
mates. Severely affected CHARGE mice even displayed a smaller brain-to-
body ratio. Further, the CHARGE mice were hyperactive and spend more
time in the center of the unknown open field maybe suggesting a maybe
less fearful nature or less understanding of their situation.
The eye phenotype had a high penetrance in the CHARGE mouse line
and an analysis showed a heterogeneity in the severity of the symptoms
with a bias towards the right eye (narrow palpebral fissures). CHARGE
eyes were significantly smaller, with a thinner retina and especially the
inner nuclear layer of the retina was significantly thinner.
PAX6 positive cells of the inner nuclear and ganglion cell layer were
found in the Control retinas. A finding that correlates to a report about
PAX6 expression in inner nuclear and ganglion cell layer in p428 in mice
(Stanescu-Segall et al., 2015). Under CHARGE conditions PAX6 positive
cells seemed reduced in comparison to their Control litter mates, but
further experiments are needed to validate this observation.
Stainings revealed that some cells of the CHARGE granular cell layer
ectopically express MASH1, a marker usually not found in the adult eye.
The cells seemed out of place since MASH1 expressing cells are usually
found in the inner nuclear layer, not in the ganglion cell layer. These
cells may correlate to the missing PAX6 development refinement. This
ectopic expression of MASH1 might reflect the underdeveloped status of
the retina, but this also needs further analysis.
The cerebella analysis could confirm a missing anterior lobe, and a
disrupted and bulky purkinje cell layer. A quantification of these cells re-
vealed that almost 30% of purkinje cells have more than three neighboring
cells under CHARGE conditions. Moreover these cells have significantly
less primary branches which all hints towards an underdeveloped brain
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structure.
Furthermore, an analysis of stem and label retaining cells of the dentate
gyrus revealed less BrdU and nestin positive cells (e.g. stem and label
retaining cells) under CHARGE conditions in comparison to their Control
litter mates.
3.3 The reCHARGE ouse
As genetic counter part to the CHARGE mouse (CMVCre;CHD7+/fl) the
reCHARGE mouse (CMVCre;CHD7+/fl;EZH2+/fl) was generated and
analyzed. As mentioned before the CMV promotor could affect the germ
line such that no in-line breedings were made.
CHARGE mice are significantly smaller. The reCHARGE mice showed
no significant difference in body weight or brain-to-body ratio (Fig. 20).
This is remarkable in the light of undergrowth reported for CHARGE
syndrome (CHD7+/fl) and overgrowth as obvious feature for Weaver
syndrome (EZH2+/fl). Here a combination of reduced CHD7 and EZH2
expression resulted in mice of average size.
3.3.1 Eyes in CHARGE vs reCHARGE Mouse
The CHARGE mice displayed closed eye lids, underdeveloped and smaller
eyes with a thinner retina and a thinner inner nuclear layer.
The reCHARGE mice had no obvious eye phenotype (Fig. 21),
and the eye structure was not significantly altered. The left and right
eye were both equally well developed and seemed structurally func-
tional. Measurements of the eye size revealed a smaller eyes (Fig. 22)
but the retina thickness was indistinguishable from the Control mice retina.
Remarkable, the reCHARGE retina phenotype showed wavy foldings
in some mice (Fig. 23C). This wavy structure could be caused by an
over-proliferation, through reduced EZH2 activity and thus reduced
H3K27me3. A wavy retina can otherwise be seen in inflammatory tissue,
but unlike retina inflammations the cell layer structure of reCharge mouse
retina comprising the cell bodies, was separated nicely into inner-, outer
nuclear and ganglion cell layer. Further analysis revealed no significant
changes in comparison to their Control litter mates.
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The question remains how the EZH2 downregulation rescues the eyes
development. One suggested candidate was PAX6, a master regulator of
the eye development. Similar to the CHARGE phenotype, an eye depen-
dent knock-out of pax6 leads to small eyes with multiple defects. In other
tissues PAX6 was already identified as EZH2 target, which was reasoned
could in hint to a possible explanation for the eased eye phenotype of
the reCHARGE mouse. Less repressive histone marks on the pax6 gene
would thus promote the expression of PAX6 and could be potentially
beneficial for the eye development. Thus, this marker was also stained in
the reCHARGE eye but revealed a likewise reduced expression, as seen in
the CHARGE mouse. These stainings hint towards a different mechanism
the normalized retinas grown under reCHARGE conditions but further
expression analysis would be needed.
A MASH1 staining showed no positive cells in the reCHARGE retina
knock-out corresponding to the results of their Control litter mates.
3.3.2 Cerebellum in CHARGE vs reCHARGE Mouse
Unlike the CHARGE mouse, the anterior lobe of the reCHARGE mouse
cerebellum showed in non of the stained mice a defect.
The purkinje cells had an average size (Fig. 26) and the phenotype of
a bulky and crowded purkinje cell layer observed in the CHARGE mouse
cerebellum was not visible in the reCHARGE mouse cerebellum (Fig. 26).
Another significant phenotype seen in CHARGE mice cerebellum
concerned the visible branches of the purkinje cells. Here in the CHD7
deficient phenotype purkinje cells with a visible primary branch were
significantly underrepresented. In contrast to that the reCHARGE mouse
purkinje cells showed as many branches as the Control mice did (Fig. 26).
Purkinje cell nuclei showed a profound EZH2 staining signal in both
CHARGE and Control mice, although the EZH2 protein level seemed to
be unaffected (Fig. 17). Purkinje cells are GABAergic neurons and as such
it has been suggested that EZH2 Controls their embryonic cell fate (Feng
et al., 2016), but this study also described cerebella hypoplasia which has
not been described under EZH2 deficiency in the Weaver syndrome and
does not fit to the known overgrowth phenotype. Furthermore, an EZH2
expression in mature purkinje cells was not described. Similar to observa-
tions made in the CHARGE mouse the purkinje cells of reCHARGE mice
displayed a nuclear EZH2 signal. However, further studies are needed to
decipherer differences between CHARGE and reCHARGE purkinje cells.
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In the future a RNA sequencing could resolve the different gene expression
of purkinje cells while CHIP and ATAC sequencing experiment could tell
more about the epigenetic status of theses cells.
3.3.3 Neural Stem Cells in CHARGE vs reCHARGE Mouse
The collected data showed that the CHARGE mouse had a lower number
of BrdU and nestin positive cells which was matching already published
data of CHD7 deficient in neural stem cells (Feng et al., 2013, supplement
Fig. 45).
To create comparable data, the reCHARGE mouse was analyzed at the
same time with the same labeling protocol used for the CHARGE mouse.
Cells were counted in a blind study. The amount of BrdU and nestin
double positive cells of the reCHARGE mouse dentate gyrus was not
significantly different from the amount of cells quantified for the Control
litter mates, thus displaying a rescue of the CHARGE condition in this
aspect.
A knock-out of ezh2 has been shown to increase the amount of stem
cells (Nestin) and newborn neurons (NeuN) in the dentate gyrus (Rhodes
et al., 2018). The loss of EZH2 and H3K27me3 seems to induce stem cell
development. This may hint towards a mechanism on how a loss of EZH2
can be beneficial for neural stem cells lacking CHD7.
To further investigate stem cells carrying a chd7 and ezh2
knock-out, an inducible homozygous knock-out was created
(NesCreERT2;CHD7fl/fl;EZH2fl/fl) and analyzed, confirming this re-
sult.
3.4 Summary of CHARGE vs reCHARGE Mouse Data
The comparison of CHARGE and reCHARGE mouse under similar condi-
tions was considered as rescue, when the reCHARGE mouse displayed no
symptoms in contrast to the CHARGE mouse.
A rescue could not be achieved in the eye size which was still sig-
nificantly smaller than the Control eye, and regarding the retina PAX6
expression. Also reCHARGE retinas were partially wavy which may
hint towards an over-proliferation. Further studies would be needed to
confirm this data. An open field analysis has not been attempted with the
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reCHARGE mouse.
Additionally, a rescue could be observed in the following experiments.
The reCHARGE mouse had in comparison to the CHARGE mouse a
normal body size, structural functional eyes, and a retina thickness that
corresponded to the measured Control values. Furthermore, the cerebella
anterior lobe was unremarkable, and the purkinje cells layer displayed
a normal structure and cells with a normal amount of visible primary
branches. A analysis of the dentate gyrus stem cells revealed a normal
amount of stem and label retaining cells in the reCHARGE mouse, unlike
the reduced amount of BrdU and nestin positive cells quantified in the
CHARGE mouse dentate gyrus.
As discussed somewhere else herein a RNA sequencing revealed that
many genes falsely regulated under CHARGE conditions corresponded to
the wildtype under reCHARGE conditions.
Taken together, a heterozygous expression of EZH2 was capable of nor-
malizing some severe symptoms reported for the CHARGE condition.
3.5 Inducible homozygous Knock-out of chd7 and ezh2
Here it could be observed that the dentate gyrus of the CHARGE mice
(CMVCre;CHD7+/fl) contains less BrdU and nestin positive cells (stem
and label retaining cells), and the same observation was made in an in-
ducible knock-out, lacking CHD7 which was restricted to the neural stem
cells (Fig. 28 and NesCreERT2;CHD7fl/fl, Feng et al., 2013 supplement
Fig. 45).
To investigate a possible rescue of the CHD7 phenotype in hippocam-
pal neural stem cells, a homozygous inducible double knock-out of chd7
and ezh2 was created. Since a homozygous knock-out of either chd7 or ezh2
is lethal, an inducible knock-out system was used and linked to a stem
cell promotor (nestin - Nes) creating a NesCreERT2;CHD7fl/fl;EZH2fl/fl
mouse line. Repeating the same timing W. Feng used to analyze his
chd7 knock-out (NesCreERT2;CHD7fl/fl) the double knock-out was
analyzed. In contrast to the CHD7 deficient neural stem cells, a homozy-
gous double knock-out of chd7 and ezh2 showed no reduction in the
amount of stem cells. Likewise animals of the running experiment showed
a normal amount of stem cells (NesCreERT2;CHD7fl/fl;EZH2fl/fl, Fig. 30).
Also, the amount of stem cells was analyzed by using a nestin staining
and counting manually all the stained cells 2 weeks, 4 weeks and 6 weeks
after the induction of the double knock-out (Fig. 29). Only 2 weeks after
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the induction of the double knock-out, the number of nestin positive
cells in the granular zone was significantly altered. The other time points
showed the same amount of stem cells in double knock-out and Control
litter mates. So there was no stem cell defect detectable in the double
knock-out.
The development of newborn neurons (MCM2, DCX) seems to be
altered in a homozygous ezh2 knock-out (NesCreERT2;EZH2fl/fl, supple-
ment Fig. 44). Preliminary data showed a dynamic reaction of the stem
cell pool to the homozygous ezh2 knock-out. Within the first 2 weeks after
the induction of the homozygous ezh2 knock-out the amount of newborn
neurons was slightly higher than in Control mice, but it dropped after
about a month past the induction in comparison to the Control mice (Li,
Y. , supplement Fig. 44). This observation initiated the analysis of MCM2
and DCX in the homozygous double knock-out of chd7 and ezh2.
Doublecortin positive cells were only 2 weeks after the knock-out
induction of the double knock-out significantly lower than the amount
counted for the Control litter mates (Fig. 32C).
Within the dentate gyrus, newborn neurons migrate from the subgran-
ular zone towards the end of the granular layer. In a stem cell dependent
ezh2 knock-out (NesCreERT2;EZH2fl/fl) more newborn neurons ex-
pressing doublecortin were observed in the upper part of the granular
layer (Li, Y., supplement Fig. 44). This could have different reasons,
for example a misguidance of the cells or a different developmental
time frame that lead to a longer doublecortin expression after the cells
reached their integration position already. However, nothing similar
has been observed in the inducible double knock-out of chd7 and ezh2
together. Cell orientation, cell distribution over the granular layer and cell
position in the complete dentate gyrus showed no difference in newborn
neurons (DCX, BrdU) compared to the Control (supplement Fig. 58, 59,
60, 61 NesCreERT2;CHD7fl/fl;EZH2fl/fl). Also, the dendritic length of
doublecortin positive cells was not significantly changed as it has been
observed in a homozygous chd7 single knock-out (Feng et al., 2013).
Corresponding to nestin and doublecortin observations, the MCM2
quantification also revealed a lower number of positive cells 2 weeks after
the knock-out induction (Fig. 33C). It seems that stem cells and newborn
neurons are reduced under double knock-out conditions but only 2 weeks
after the induction of the knock-out.
This could be explained in different ways. Considerable evidence
has shown that tamoxifen administration can be neurotoxic, resulting in
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impaired learning in rodents (Eberling et al., 2004). Thus, a time dependent
reduction in the amount of stem cells might be an artefact of the tamoxifen
treatment. However, this would be a general phenomenon, and in the
presented case only the mutant mice displayed this deficit while the
tamoxifen treated Control did not show a reduced stem cell amount.
Developing neural stem cells might be sensitive to the knock-out of
chd7 and ezh2 at a certain time point. The development of neural stem cells
to mature neurons, takes about eight weeks in the mouse dentate gyrus.
Within the first days a type I and type II stem cell still expresses nestin,
before the fate determination is finished in type III stem cells around the
end of the first week. Now markers like MCM2 and doublecortin are
expressed, until around the second week when these markers for newborn
and immature neurons are followed by NeuN and Calretinin (Duan et
al., 2008). The balance between neural stem cell self-renewal and cell
differentiation is maintained, through epigenetic processes and especially
CHD7 and EZH2 have both been linked to the cell fate decision. It was
reported that EZH2 plays an important role in the temporal regulation
of neural progenitor cells, prolonging the neurogenic phase. The levels
of H3K27me3 would gradually increase over time at the ngn1 promoter,
and it would be plausible that, at a certain threshold, their chromatin state
would become inactivated by PRC1, resulting in the suppression of ngn
expression and the transition of NPC fate. In this report it was proposed
that the developmental-stage-dependent accumulation of H3K27me3
at specific gene loci functions as a timer to drive cell fate switching
(Hirabayashi et al., 2009). Fate confusion could, in theory, lead to an
unfinished development and ultimately to cell death.
At a later time point the cell amount of all tested markers normal-
izes in the double knock-out (NesCreERT2;CHD7fl/fl;EZH2fl/fl). This
may reflect a compensatory mechanism or a balance of both chromatin
remodeler after a rough transition phase. It also might make a difference
to developing stem cells, wether the cells were growing under a reduced
CHD7 and EZH2 level from the beginning, or if said cells lost them at a
maybe critical time point during the development.
A homozygous knock-out of chd7 leads to an increased pro-
liferation (Ki67) in the subgranular zone of the dentate gyrus
(NesCreERT2;CHD7fl/fl, Feng et al., 2013, supplement Fig. 45). Quantified
four weeks after the knock-out induction the amount of proliferation
seemed normal when both chd7 and ezh2 were knocked-out together (Fig.
31, NesCreERT2;CHD7fl/fl;EZH2fl/fl). No difference could be observed.
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3.6 Summary of the inducible homozygous chd7 and ezh2 Knock-
out
A homozygous double knock-out of chd7 and ezh2 had a normal amount of
BrdU labeled cells. An investigation over several weeks showed only two
weeks after the knock-out induction a significant reduction in stem cells,
and newborn neurons (nestin, DCX, MCM2). At four and six weeks, no
difference between the mutant mice and their Control litter mates could be
observed.
Further doublecortin positive cells showed no abnormalities in cell
distribution, cell orientation and dendritic length (data shown in sup-
plement). Also, the proliferation, measured by Ki67 positive cells was
unremarkable in a homozygous double knock-out of chd7 and ezh2.
In summary the double knock-out of textitchd7 and ezh2 could rescue
the chd7 knock-out phenotype in neural stem cells of the dentate gyrus.
3.7 Treatment with the EZH2 Inhibitor GSK126
Since the CHARGE syndrome is a developmental disease the question
remained wether the situation of already affected patients could be
eased through a stem cell treatment. This question was linked to further
questions. What is the effect of a chd7 knock-out on different not yet
investigated brain regions. Is the structure disrupted in a way that new
healthy stem cells would be capable of changing the signal output? Could
an EZH2 inhibitor have a negative effect on otherwise non affected brain
regions?
To further investigate these questions a few in vitro pre-tests and in vivo
experiments were conducted.
3.7.1 In vitro - CHD7 Knock-down Cells tolerate a Treatment with the
EZH2 Inhibitor
Cells carrying a stable chd7 knock down were analyzed in regard to their
CHD7, and EZH2 expression via qPCR and showed a significant downreg-
ulation of CHD7.
These cells were further cultured and treated with the EZH2 inhibitor
GSK126 with either 0, 1 or 2 µM of the GSK126 EZH2 inhibitor. The cells
tolerated this treatment, and the inhibition of EZH2 was successful after 72
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hours of treatment, shown by western blot for H3K27me3.
Another test was the treatment of HEK293T and neural stem cells with
different versions of the GSK126 EZH2 inhibitor chemically altered to
maybe later be capable of crossing the blood-brain-barrier. The H3K27me3
protein level was reduced in HEK293T and neural stem cells. However,
the reduction on neural stem cells seemed not clearly concentration
dependent, which may reflect the chemical alteration which may alter the
inhibitory function of this specific inhibitor.
3.7.2 In vivo - the EZH2 Inhibitor can be Administered to the Brain and
reduces H3K27me3 Protein Level
To further investigate whether the EZH2 inhibitor GSK126 could be a
potent CHARGE medication, a brain application was designed. Since the
inhibitor does not cross the blood-brain-barrier the brain infusion was
achieved through an osmotic pump. With an infusion period of five days
constantly infusing 2 µM of the GSK126 inhibitor with 0.5 µl per hour in
the right dentate gyrus. The surgery procedure could be established and
seven mice survived the treatment. Unfortunately all of them were Control
mice and only some received an inhibitor treatment.
Combining the inhibitor treatment with CldU it could be shown that
the infusion into the dentate gyrus effectively labels cells with CldU. This
occurred in a limited fashion as cells of the left dentate gyrus displayed no
CldU signal. Further it could be shown that H3K27me3 level of the dentate
gyrus tissue were reduced in two treated mice (Fig. 35I).
3.8 Summary of the Treatment with the EZH2 Inhibitor GSK126
A CHD7 knock down cell line can be treated with the EZH2 inhibitor
GSK126 and displays a reduced H3K27me3 level after 72 hours of incuba-
tion.
Different chemical altered versions of GSK126 were tested on HEK293T
cells and on neural stem cells to reveal functional alterations of the GSK126
inhibitor22.
Testing the brain compatibility of the non-altered version of the EZH2
inhibitor GSK126 an osmotic pump was surgically fixed to the mice den-
22In a next step the chemical variations reducing H3K27me3 will be tested in an in vitro
model of the blood brain barrier. This will be conducted outside the scope of this project.
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tate gyrus. A combination of the inhibitor with CldU revealed that even
after five days of constant infusion, only one brain hemisphere contained
marked cells. Maybe suggesting that only a regional effect of the inhibitor
can be obtained by this approach. However, the infusion was capable
of reducing H3K27me3 protein level in the brain tissue. Unfortunately
the treatment was not tolerated by the chd7 knock-out mice while some
Control mice survived.
3.9 RNA Sequencing of CHD7+/fl and CHD7+/flEZH2+/fl Cere-
bellum Tissue
Given the before mentioned results a RNA sequencing was intended to
give new insights into the differentially expressed genes under CHD7 or
CHD7 and EZH2 loss.
To further investigate the cerebellum tissue of Control (CMVCre-
), CHARGE (CMVCre;CHD7+/fl) and reCHARGE mouse
(CMVCre;CHD7+/flEZH2+/fl), the RNA of half of the cerebellum
tissue was isolated and tested via qPCR. The expression level of CHD7 and
EZH2 and confirmed the reduction of CHD7 in CHARGE and a reduced
CHD7 and EZH2 expression level in reCHARGE mouse (Fig. 36A and B).
The analysis of the RNA sequencing data revealed that significantly
changed genes showed similarities within the group of CHARGE and
Control animals. The reCHARGE mouse tissue however had an expression
pattern closer to the Control mice and the gene expression of several genes
was rescued under reCHARGE conditions.
An analysis of the RNA sequencing data of all regulated genes in
CHARGE vs Control mice revealed that processes for regulation of tran-
scription, DNA-template, and nucleosome assembly are significant altered.
Remarkably, also H3K27me3 appeared in the list of significantly changed
genes (supplement Fig. 49), and intriguingly processes of chromatin
silencing are up-regulated (supplement Fig. 50). A missing re-activation
of genes through loss of CHD7 led to increased chromatin silencing under
CHARGE conditions. This result underlines the main hypothesis of this
work. Further studies are needed to reveal the molecular pathways how
CHD7 influences chromatin silencing.
Further up-regulated genes in CHARGE vs Control cerebellum tissue
include DNA methylation on cytosine, regulation of gene expression and
epigenetic, DNA replication-dependent nucleosome assembly, protein het-
erotetramerization, chromatin silencing at rDNA and especially regulation
of transcription (supplement Fig. 50).
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Downregulated are cell differentiation, cell transport and mRNA pro-
cessing. Interestingly, also Rho protein signal transduction and filopodium
assembly were downregulated under CHARGE conditions. A misregu-
lation in the Rho family of small Ras-related GTPases can interfere with
cytoskeleton formation and filopodium assembly (Ohta et al., 1999). Neu-
rons deprived of filopodia display defects in growth direction and synaptic
formation (Bentley et al., 1986; Bardsley et al., 1999; Maletic-Savatic et al.,
1999). The regulation of synaptic plasticity was likewise downregulated in
the CHARGE cerebellum tissue (supplement Fig. 51).
Interestingly, a study analyzing CHD7 up-regegulation in glioblastoma
found that altered genes were highly associated with pathways such
as biological adhesion, cell adhesion and locomotion in gene ontology (GO)
analysis (Machado et al., 2019). In the cerebellum tissue of the here ana-
lyzed CHARGE mouse cell adhesion and angiogenesis were significantly
downregulated (supplement Fig. 51).
All significantly changed genes are summarized in a volcano plot
(Fig. 38B) depicting the genes rescued under reCHARGE conditions in
comparison to CHARGE mouse cerebellum tissue. The rescued genes
cover a part of the significantly changed genes, but not all significantly
changed genes. This fits to the expectation of a partial rescue seen in
the reCHARGE cerebellum. Especially the downregulated genes found
under CHARGE conditions are rescued quite efficiently. This observation
could be related to the reduced EZH2 expression of reCHARGE mouse
reduces the repressive histone mark H3K27me3 and is capable of gene
activation. To further investigate this CHD7 target genes would need to be
investigated regarding their H3K27me3 level.
The RNA sequencing of the complete cerebellum tissue can hint
towards misregulated over all processes which might hint towards altered
processes in the cerebellum of CHARGE patients. From this starting point
more detailed investigations, maybe analyzing different cell types, can
follow.
3.10 Summary of all Data
Within the framework of this project, a CHARGE mouse
(CMVCre;CHD7+/fl) and a genetic rescue the reCHARGE mouse could
be generated and analyzed. The reCHARGE mouse displayed a partial
rescue of most of the analyzed CHARGE symptoms. The reCHARGE
mouse had in comparison to the CHARGE mouse a normal body size,
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structural functional eyes, and a retina thickness that corresponded to the
measured Control values. Furthermore, the cerebella anterior lobe was
unremarkable, and the purkinje cells layer displayed a normal structure
and cells with a normal amount of visible primary branches. Moreover
a RNA sequencing revealed that many genes falsely regulated under
CHARGE conditions corresponded to the wildtype under reCHARGE
conditions. A analysis of the dentate gyrus stem cells revealed a normal
amount of stem and label retaining cells in the reCHARGE mouse, unlike
the reduced amount of BrdU and nestin positive cells quantified from the
CHARGE mouse dentate gyrus.
Furthermore, the EZH2 inhibitor was tested on CHD7 knock down
cells and neural stem cells and was capable of reducing H3K27me3.
A brain application was established and revealed that EZH2 inhibitor
infused tissue has a reduced H3K27me3 level.
3.11 Future Perspective
The herein collected and presented data shows a rescue of the CHD7 single
knock-out phenotype in many aspects. A further investigation could focus
on the genetic properties of purkinje cells and granular neurons carrying a
ezh2 and chd7 knock-out.
Also, BrdU positive cells in the CHARGE and reCHARGE retina
would be interesting to analyze to decipherer a possible developmental
defect under CHARGE conditions and a possible over-proliferation in the
reCHARGE retina.
Another interesting experiment would be a complete behavior profile
of CHARGE and reCHARGE mouse, ad best both mouse lines would be
Controlled against an eye or inner ear phenotype. An analysis could focus
on aggressive behavior or sleeping abnormalities.
Furthermore, the surgical application of the EZH2 inhibitor GSK126
could give new insights into a possible treatment of stem cells under
CHARGE conditions. Since the H3K27me3 protein level could be de-
creased with this treatment, a analysis of the stem cell pool and a possible
rescue of the same would be an interesting experiment.
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4 Material and Methods
4.1 Mouse Lines
All mouse lines were breed and housed in the DKFZ animal facility (barrier
5) under standardized conditions (temperature, humidity). The genetic
background was a C57BL/6N-C2 mouse for all crossed mouse lines.
CHD7+/fl mice were obtained from EUCOMM, and the neomycin
selection cassette was removed by crossing with Flp deleter mice. Ne-
sCreERT2, NesCrefl/fl and animals were generated as described elsewhere
(Corsini et al., 2009).
CMVCre mice were provided by Prof. Augustin and are described as
follows. In this transgenic strain, deletion of loxP-flanked genes occurs in
all tissues, including germ cells. The cre gene in this strain is under the
transcriptional Control of a human cytomegalovirus minimal promoter
and is likely to be expressed before implantation during early embryo-
genesis. It also appears that the cre gene is X-linked since transgene
transmission through males is restricted to female offspring23.
The NesCreERT2 double knock-out of CHD7fl/fl and EZH2fl/fl was
crossed between the single knock-out lines.
To induce the knock-out in NesCreERT2 mouse lines Tamoxifen (Sigma,
T-5648-5G, 10 mg/ml) was used. Diluted in 4.5 ml sunflower oil (Sigma,
S-5007) and 500 µl EtOH, Tamoxifen was injected intraperitoneal (i.p.)
twice per day on 5 following days.
For BrdU injections 15 mg/ml were dissolved in sterile NaCl and heat
up to 50◦C. Injected were 50 mg/kg once per day. Mice that could not be
injected got BrdU in the feeding water with a concentration of 1 mg/ml for
1 week.
Experiments conducted with these mouse lines were proceeded under
the allowance of the german regional animal welfare commission. Two
animal experiment applications were written in for this project (G-278/15,
G-285/16), both were granted by the german regional council.
23The Jackson Labratory, https://www.jax.org/strain/006054
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Figure 39: Used mouse lines with reference name and explanation of the
genotype
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Figure 40: Genotyping primer for different mouse lines
4.1.1 Genotyping
To determine the genotype of the different mice, tail biopsies were taken.
The tail pieces were digested in 200 µl NID buffer (50 mM KCl; 10 mM
Tris-HCl, pH 8.3; 2 mM MgCl2; 0.1 mg/ml Gelatin; 0.45% NP40; 0.45%
Tween 20) with 2 µl Proteinase K (10 mg/ml). After an over night incu-
bation at 56◦C the mixture was finally incubated at 96◦C for 10 minutes
and briefly centrifuged. For a standard PCR 1-2 µl DNA solution was used.
With a standard protocol only the annealing temperature was changed
according to the primer requirements. Together with a DNA marker the
samples were visualized with gel red on a 2% electrophorese gel after
running for 1 h at 130 V. Pictures were taken and the analyzed genotyping
results were included into a mouse data base (Tierbase, Movi).
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4.1.2 Running Experiment
Litter mates of the same age (10 weeks) got 5 days of Tamoxifen injection
(10 mg/ml, 100 µl twice per day). After another two weeks the stem and
label retaining cells were marked by BrdU at 5 days of injection. With the
last day of BrdU injection the mice were transferred into running cages
and the following four weeks three to four mice per cage shared one
running wheel. Then these mice were sacrificed with CO2, perfused and
the dissected brain was fixed in 4% PFA. To recognize BrdU positive cells
an antibody was used (Fig. 30).
4.1.3 Pump Surgery
Before the surgery, the osmotic pumps need to be assembled and filled with
the EZH2 inhibitor GSK126 under steril conditions. A 2 µM concentration
of GSK126 was used. Under a cell culture hood the pumps are unpacked,
filled by using a needle and fixed together. This means the cannula was
fixed to a metal part connecting it to the pump. The fixed and filled pumps
are kept in a 50 ml Falcon in NaCl and are sterilized right before use with
100% EtOH and rinse in fresh NaCl.
For the procedure, eight to ten week old litter mate mice were used
(NesCreERT2;CHD7fl/fl). The mice got Tamoxifen (10 mg/ml) twice
per day, injected i.p. and after two more weeks the pump surgery was
performed.
To prepare the surgery a heating mat was warmed and placed in front
of a head holder for stereotactic injections. Natriumchlorid, Ketamin/
Xylazin in NaCl (1 ml / 0.5 ml/ 8.5 ml, 10 µg/g) were prepared in a
syringe, eye creme, clean surgical tools in 100% Ethanol bath, and a needle
with surgical suing material was prepared.
The mice were deeply anesthetized with Ketamin/ Xylazin in NaCl
and prepared for the surgery by shaving, fixing the skull into a stereotactic
head holder (Kopf) and disinfecting the skin.
A small incision opened the view from the skulls bregma to the hind
head. To form a small pocket under the skin, blunt-ended sizers are
positioned under the skin on the back of the mouse and softly opened.
Later on, the pump will be positioned in this pocket. Subsequently a
long glass needle was fixed to the stereotaxic apparatus and placed right
above bregma. The system was set to zero and the dentate gyrus was
targeted by using the following coordinates x +/- 1.6, y -2.0, z -2.3. Under
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the microscope this exact position was used to open the skull with a needle.
While opening the skin pocket with forceps, the pump was positioned
on the back of the mouse. The skull hole was cleaned and a tiny bit of a
fluid glue was distributed in a circle around the hole. The insertion needle
was pushed through the hole in the skull and the plastic tap was glued to
the skull. While the glue dried, the plastic cap on top of the tap was cut-off,
and the skin insertion was sewn with surgical filament. After releasing the
mouse out of the stereotaxic head holder, every mouse got another shot of
diluted Ketamin (1:10 in NaCl) and was placed on a heating mat with 37◦C
and monitored while waking up. Pain killers were given ad libitum in the
drinking water (Fig. 35).
4.2 Stainings
The brains of perfused mice were fixed with 4% Paraformaldehyde in
PBS over night, and then cut into 40 µM slices with a Vibratome (Leica).
Brain sections were kept in PBS and washed with fresh PBS before staining.
Eyes and brains used for H & E stainings were fixed with 4%
Paraformaldehyde in PBS over night, orientated in a wax block. Eyes were
washed two times for 15 minutes in PBS, slowly dehydrolized by reducing
the PBS content and increasing the alcohol amount. Meaning that after
two times of 30 minutes incubation with 70% alcohol, two times one hour
incubation with 85% and 95% alcohol followed subsequently. The eyes
stayed over night in pure alcohol and were put in xylene for two hours on
the next morning. Paraffin or wax was added with 60◦C and exchanged
against new paraffin after another hour. Finally the eyes were placed in the
plastic mold and paraffin was added and dyed. Eyes were cut into 6 µM
parrafin sections, and sections with a visible pupil and optic nerve were
selected for stainings.
4.2.1 Immunofluorescence
To reduce autofluorescence, the fixed brain slices were kept in PBS with
100 mM Glycine before blocking them in 5% NSS (diluted in PBST (PBS
0.2% Triton X)) for 30 minutes. If BrdU was stained the sections were
treated with 2N HCl at 37◦C before blocking them. After washing the
tissue, the secondary fluorescent antibody and 1:10000 DAPI diluted in
5% NSS (diluted in PBST) incubated for 1 hour. With a final washing step
the sections were mount on glass objectives with Eukitt for fluorescent
stainings. Fluorescent images were taken with confocal laser-scanning
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Figure 41: Primary antibodies used for IF and IHC stainings
microscopes (LSM780, LSM700, Zeiss) (Fig. 30, Fig. 14, Fig.17, Fig. , Fig.
24).
4.2.2 Immunohistochemistry
Fixed brain sections were kept in PBS and washed with fresh PBS before
staining, and then incubated in 2 M HCL for 30 minutes at room tem-
perature. After three more PBS washing steps a mixture of 0.6% H2O2
dilution in 1:1 PBS/Methanol was used to block endogenous peroxidase.
To remove membrane proteins the samples are washed three times for 15
minutes with PBST (PBS 0.2% Triton X). Then the tissue was blocked for 30
minutes with a solution of 5% NSS in PBST to reduce unspecific antibody
binding.
An incubation with the first antibody diluted in 5% NSS PBST at four
degree takes a night. Left over antibody was washed away in three PBST
washing steps. The biotinylated secondary antibodies (Donkey anti-goat
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Figure 42: Secondary antibodies used for IF and IHC stainings
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and donkey anti-mouse, Vector Laboratories) were diluted in 5% NSS
PBST and left for 30 minutes on the slices, before left over solution was
washed away by another turn of three PBST washing steps. While the
samples were washing the AB-Complex was diluted 1 to 100 in PBST, and
incubates at room temperature. After the last washing step the horseradish
peroxidase system (ABC Kit, Vector Laboratories) or short AB-Complex
solution was added to the tissue, and incubated for 30 minutes. With the
following two washing steps, first PBST and then PBS the samples were
ready to be visualized by DAB staining (Sigma-Aldrich). The reaction
can be stopped after 5 minutes by tap water, and the stained tissue was
transferred to a glass objectives and dried for at least 30 minutes before
mounting them with Eukitt and a glass cover slip. Bright field pictures
were taken with a basic microscope (Fig. 29, Fig. 32, Fig. 33, Fig. 26, Fig.
27, Fig. 28).
4.2.3 Haematoxilin and Eosin Staining
An Haematoxilin and Eosin staining was used on paraffin sections to
show structural differences in the brain tissue. In a first step the paraffin
surrounding the brain was removed by washing with Xylene, and then
re-hydrolyzed by two decreasing alcohol concentrations (100% and 70%).
The Haematoxylin solution remains for 8 minutes on the brain sections and
was removed by rinsing water after this time period. After adding Eosin
(0,1% in 70% EtOH) for 1.5 minutes the brain sections are de-hydrolyzed
again by increasing alcohol concentrations and a final Xylene washing
step. With a cover glass and Eukitt mounting medium the stained brain
slices can be covered and analyzed after dried (Fig. 8, Fig. 12, Fig. 13, Fig.
16, Fig. 22, Fig. 23, Fig. 25).
4.3 Western Blot
In brief, a abcam western blot protocol was used24 and the Imobilon
Western Chemoluminescent HRP Substrate protocol from Milipore was
used for the chemoluminscent detection. Dissected and snap frozen brain
tissue was mechanically homogenized in lysis buffer, and sonicated for 10
minutes per sample. After spinning the samples for 20 minutes at 12000
rpm and 4◦C, the supernatant was collected and the protein concentration
was measured by wavelength using a Nano drop.
24https://www.abcam.co.jp/ps/products/131/ab131366/documents/Western%20blotting%20-
%20a%20beginner’s%20guide.pdf
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The volume for 20 µg protein was calculated and the samples diluted
1 to 6 in laemmli buffer. Right before loading the sample on a precast gel
(Mini-Protean TGX 10% and 12%, Biorad) the samples were heated to 99◦C
for 5 minutes. The precast gels were placed into a western blot running
cassette and filled with with 1x Tris-glycine running buffer. With 80 V for
30 minutes, and 120 V for another hour the samples were separated by size
in the electrophorese gel.
After a sufficient size preparation the gel-bound-protein was coupled
to a nitrocellulose membrane and surrounded by thick buffer soaked
papers to form a wet blot sandwich. For big proteins like EZH2 and CHD7,
the transfer (in 100 ml 10x Tris, 200 ml Methanol and 700 ml H2O) was
obtained at 100 V for 1 h.
To visualize the transfer quality, a Ponceau Red (2% Ponceau S, 30%
trichloracetic acid, 30% sulfosallicylic acid) protein indicator fluid was
incubated for 5 minutes, analyzed and then washed off with PBST (1000 ml
PBS and 1 ml Tween20). Floating in a 5% milk the membrane was blocked
for 1 h at 4◦C to reduce non-specific antibody binding. After a brief
washing step in PBST, the membrane was cut into pieces and incubated
over night at 4◦C with the first antibody diluted 1 to 1000 in PBST.
For the incubation with the secondary antibody, the membrane was
briefly washed with PBST and then incubated for 1 h at room temperature.
The secondary horseradish-coupled antibody is diluted 1 to 4000 in PBST
and visualized with chemiluminescent HRP substrate (Millipore). An
equal amount of luminol reagent and peroxide solution was mixed and
used when reached room temperature. After an incubation of 5 minutes
the left over substrate fluid was removed, and the membrane was covered
in transparent foil and a picture was taken (Fig. 34).
4.4 RNA Isolation and cDNA Preparation
In brief, a RNAprep combining Trizol (TRI Reagent Protocol, Sigma-
Aldrich) and colums (RNeasy Mini Kit, Qiagene) was used.
Snap frozen tissue −80◦C was mechanically homogenized in 500 µl TRI
reagent and incubated for 5 minutes at room temperature. After adding
100 µl Chloroform the samples were mixed and incubated for 5 minutes
at room temperature. The following centrifugation (12000 rpm, 4◦C, 20
minutes) separated the RNA from the Protein and DNA content. The
aqueous phase was then processed mixed with fresh mixed 70% alcohol
and the RNeasy protocol was followed. Briefly the precipitated RNA was
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Figure 43: Primary antibodies used for western blot
filtered and washed through silica colums and eluated. The concentrations
were measured by wavelength using a NanoDrop system (Thermofisher).
To transcribe the RNA to cDNA a QuantiTec Reverse Transcription Kit
(Qiagen, 205310) was used according to the protocol.
4.4.1 qPCR
With the resulting cDNA, a qPCR was set up using a TaqMan gene
expression assay protocol. In a 20 µl reaction 1 µl primer (20x TaqMan
Gene Expression Assay), 10 µl enzyme (TaqMan Gene Expression Master
Mix), 4 µl cDNA template and 5 µl RNase free water was mixed. The
standard protocol had a 60◦C annealing temperature for all primers and
the program loop was repeated for 40 to 50 times. In this system the primer
mix contains two flanking primers and one carrying the Fluorophor (FAM
primer). With increasing amount of PCR product the amount of bound
FAM primer increases and leads to a measurable fluorescent signal. With
a qPCR machine (Biorad), the product amount and starting quantity (SQ)
was analyzed (Fig. 8, Fig. 19, Fig. 36, Fig. 34.
Alternatively a cybergreen qPCR system was used which quantifies
the amount of resulting DNA through intercalating into the DNA. If this
system was used it is indicated, otherwise TagMan probes were used (Fig.
34).
Relative expression level were calculated as follows: the house keeping
gene was subtracted from the tested gene of mutant and Control mice
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(calculating the delta CTE and delta CTC value). The delta CTC value was
subtracted from the delta CTE value to calculate the delta-delta CT value.
In the last step 2−deltadeltaCT value was calculated and the values of gene
expression were compared.
4.4.2 RNA Sequencing
The cerebellum of the dissected brain was cut in half and one half was
snap frozen. After isolating the RNA and producing the cDNA according
to 4.4 RNA isolation and cDNA preparation, the cDNA was analyzed via
qPCR (4.4.1 qPCR). Samples were selected, diluted in water in a 96 well
plate on ice, and send on ice for sequencing to the DKFZ core facility. (The
resulting raw data was kindly analyzed by C. Shao.)
4.5 Cell Culture
4.5.1 Neural Stem Cell Culture from Adult Mouse Subventricular Zone
Neural stem cell were isolated as described elsewhere (Fischer et al., 2011).
In brief, eight weeks old mice were used and the subventricular zone was
isolated. The collected tissue was cut into small pieces and collected in
a 2 ml tube. After centrifuge for 1 minute at 250 g the supernatant was
removed under a cell culture hood, and 1 ml of Accutase was added to the
brain tissue. It takes around 20 minutes at 37◦C to separate the cells and
this can be improved by pipetting up an down or filtering through a blue
cap tube. With another centrifugation (5 minutes at 250 g) the supernatant
was removed and the cells are resuspended in fresh serum free medium
(DMEM/F12 (1:1) + L glutamine and 15 mM HEPES (Invitrogen cat.
no.11330-032), growth factors (EGF (Sigma cat. no. E4127), FGF (Sigma cat.
no. F0291)), B-27 and ITSS).
Neural stem cells of the subventricular zone can be cultured as spheres
or as attached monolayer in serum free medium (SFM) at 37◦C with 95%
air and 5% CO2. For a monolayer culture dishes have to be coated with
coating buffer (Laminin (0.5 mg/ml, Roche 11243217001) 250 µl, PDL/PLL
(2 mg/ml in H2O, Sigma P7280-5mg) 750 µl, PBS to 50 ml) for at least 4
hours at 37◦C. After this incubation time the coating buffer was removed
and the plates were dried under UV light in a cell culture hood (NSC
monolayer Fig. 34).
To passage these cells, either the medium with the floating spheres was
collected, centrifuged, the supernatant removed and 1 ml of Accutase was
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added, or the medium was carefully removed from the monolayer and 1
ml Accutase was added. It took 10 minutes of incubation at 37◦C until the
cells were separated and after another centrifugation the left-over Accutase
was removed within the supernatant. Finally the cells were resuspended
in fresh serum free medium and plated on either a coated or a non-coated
plate.
When cells were frozen they were passaged as mentioned and re-
suspended into a different medium in the last step. This serum free
medium did not contain growth factors (SFM is DMEM/F12 (1:1) + L
glutamine and 15 mM HEPES (Invitrogen cat. no.11330-032)) but 10%
dimethyl-sulfoxide (DMSO) instead. The cell suspension was gently mixed
and aliquoted with 1 ml into polypropylene cryovials (Nunc Cryo Tubes
cat. no. 357418) and frozen at −80◦C using Cryobox.
To defrost the cells the cryo-vials were gently warmed up to 37◦C,
mixed with fresh serum free medium and centrifuged (5 minutes at 200
g). The supernatant was removed and the cells were either seeded as
monolayer of neurosphere with 95% air and 5% CO2 as mentioned (Fig.
53, Fig. 34).
4.5.2 EZH2 Inhibitor Treatment
The EZH2 inhibitor GSK126 (in PBS/ 10% DMSO) was used for different
purposes.
For treating cultured cells the inhibitor was mixed with the cell medium to
a final concentration of 0, 1 and 2 µM and incubated for 48 and 72h (Fig.
34, Fig. 53).
As a drug for treating neural stem cells in the living animal the inhibitor
was diluted in NaCl to a final concentration of 2 µM, filled into a osmotic
pump under sterile conditions, and the loaded pump was kept in 70%
EtOH in a 50 ml Eppendorf tube with closed litt. Right before positioning
of the pump the EtOH was washed away with steril NaCl (Fig. 35).
4.6 Plasmid Multiplication and Isolation
Plasmids were multiplied via heat shock into DH5alpha E.coli. In brief, the
competent bacteria was thaw on ice and the plasmid DNA was added with
a buffer. The bacteria was heated for 42◦C for 2 minutes and cells were
placed on ice again. The prepared E.coli were distributed on culturing
plates carrying a antibiotic. The antibiotic was selected due to the antibiotic
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resistance gene on the respective plasmid wished to multiply. After an over
night incubation the growing bacteria colonies were picked and placed in
liquid LB medium (800 ml H2O, 10 g Bacto-tryptone, 5 g yeast extract and
10 g NaCl, pH 7.5 sterile). Another incubation of at least three hours was
set to multiply the bacteria carrying the plasmid. After this incubation the
bacteria was centrifuged an the plasmid was isolated by using a QIAprep
Spin Miniprep Kit following the kit instructions.
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5 Appendix
5.1 List of Abbreviations
in vivo Experiments in the living organism
in vitro Experiments in the lab
kDa kilodalton
EDTA Ethylenediaminetetraacetate
BSA Bovine serum albumin
BrdU 5-bromo-2-deoxyuridine
IdU 5-Iodo-2-deoxyuridine
CldU 5-chloro-2-deoxyuridine
Cre DNA recombinase
DKFZ Deutsches Krebsforschungs Zentrum
EtOH Ethanol
PBS Phosphat buffer saline
DAPI 4,6-diamidino-2-phenylindole
RNA Ribonucleic acid
DNA Deoxyribonucleic acid
CHIP Chromatin Immunoprecipitation
SFM Serum free medium
FBS Fetal Bovine Serum
NSC Neural stem cells
SVZ Subventricular zone
DG Dentate gyrus
OB Olfactory bulbs
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Figure 44: Y. Li unpublished, staining and quantification of Doublecortin
and MCM2 (Nestin Cre EZH2fl/fl)The knock-out was induced in ten week
old mice. After the knock-out induction mutant and Control litter mates
were analyzed 0.5, 1, 2, and 5 month later. After staining the positive cells
were count manually.
Figure 45: From W. Feng et al. 2013, quantification of BrdU positive
and Ki67 positive cells (NesCre;CHD7fl/fl) The knock-out was induced
in eight week old mice. After the knock-out induction mutant and Control
litter mates were analyzed after four weeks voluntary running (BrdU) and
directly after the induction (Ki67). Stained cells were count manually.
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Figure 46: From W. Feng et al. 2017, p7 Fig. 4c DAVID Gene Ontology
Biological Process analysis of genes downregulated in Chd7 homozygous
mutant GNPs compared to WT. GO terms with Benjamini adjusted P-value
0.05 are shown (Atho1::Cre CHD7fl/fl).
5.2 Supplement Data
5.2.1 Published Data - W. Feng et al., 2013 and 2017
5.2.2 Reelin on CHARGE cerebellum tissue
Shown in Feng et al., 2017, Reelin is regulated by CHD7 in cerebella
granular neurons. This finding initiated a small scale analysis of Reelin in
the CHARGE mouse. Figure 48 depicts immunofluorescence pictures of
Control and CHARGE mouse cerebellum (A) and qPCR results for CHD7
and Reelin with two mice per genotype in graph B and C respectively.
Reelin is secreted by granular neurons and taken up by purkinje cells,
thus the staining shows a cytosolic signal for Reelin in the Purkinje cells
of Control mice. The signal for CHARGE mouse purkinje cells looks
less cytosolic and is hinting towards a nuclear signal distribution (A,
CMVCre;CHD7+/fl). The preliminary qPCR results show a reduced CHD7
signal and a reduction in the relative expression of Reelin both in the
CHARGE mouse cerebellum (graph B and C). Three animals were tested
via qPCR, one animal was excluded as outliner.
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Figure 47: From W. Feng et al. 2017, p.4 Fig. 2 a, deformations under
CHD7 deficiency Nissl staining of E15.5, P0, P7 and adult cerebella includ-
ing vermis and hemisphere from [Chd7fl/fl] and [Atoh1-Cre::Chd7fl/fl]
mice. Left side in each panel is the anterior part of cerebella. Scale bars,
100 mm.
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Figure 48: Immunofluorescence picture and qPCR graph for reelin in
the cerebellum (Control and CHARGE mouse) A: Stained cerebellum
slices of the ten week old Control (CMV Cre-) and CHARGE mouse
(CMVCre;CHD7+/fl) cerebellum were treated with antibodies against
reelin (1:200, Merck Millipore, 488) and DAPI (1:10000) and pictures were
taken with a laser microscope (LSM780, Zeiss). B: qPCR of CHARGE
mouse analyzing the relative expression level of CHD7 in Control (CMV
Cre-) and mutant (CMVCre;CHD7+/fl) mice cerebellum tissue. C: qPCR of
CHARGE mouse analyzing the relative expression level of reelin in Con-
trol (CMV Cre-) and mutant (CMVCre;CHD7+/fl) mice cerebellum tissue.
N-values represent animal numbers.
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Figure 49: List of significantly regulated genes (CHARGE vs Control)
This list has been kindly provided by C. Shao
Figure 50: List of significantly regulated genes (CHARGE vs Control)
This list has been kindly provided by C. Shao
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Figure 51: List of significantly regulated genes (CHARGE vs Control)
This list has been kindly provided by C. Shao
5.2.3 RNA Sequencing - Lists of significantly changed Processes
5.2.4 An in vitro double knock-out hints towards no reduction in key
transcription factors
To further investigate the characteristics of neural stem cells with floxed
ezh2 and chd7 genes (CHD7fl/fl;EZH2fl/fl), the neural stem cells of three
animals were isolated, cultured and transfected either with a CAG-
Cre-IRES-GFP (inducing the knock-out), or a CAG-IRES-GFP virus (not
inducing the knock-out).
The virus was produced in HEK293T cells, and subsequently the neural
stem cells were transfected with this virus (Fig. 52A). After another four
weeks of expanding the transfected neural stem cells, these cells were FAC
sorted for GFP. Out of six induced/ not induced cell line combinations,
four cell lines could be sorted, ranging from a transfection rate between 30
and 50% (Fig. 52 example in B).
In a qPCR analysis the expression of the not-Cre-induced cell line
(CAG-IRES-GFP) was taken as 100% while the three cell lines treated with
the Cre recombinase virus are shown together. Both CHD7 and EZH2
range around a relative expression level of 30% and 50% respectively, while
the key regulators SOX4, SOX11 and PTEN are not altered in comparison
to the Control cell line (Fig. 52C). This is especially intriguing because a
chd7 single knock-out in neural stem cells showed a reduction in the SoxC
transcription factors SOX4 and SOX11.
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Figure 52: Neural stem cells carrying the double knock-out (CHD7
fl/fl and EZH2fl/fl ) show no reduction in the expression level of
key transcription factors (cell lines with and without knock-out)
A: Through-light and GFP fluorescent pictures of viral transfected
HEK293T cells and neural stem cells (NSC) treated treated with/ with-
out Cre-IRES-GFP virus and IRES-GFP virus, respectively. B: Exam-
ple results of the FAC sorting for GFP. Shown is a Control (CAG-IRES-
GFP). C: qPCR for the relative expression level of CHD7, EZH2, SOX4,
SOX11, and PTEN in the sorted NSC cells. The sample size n=1 Control
NSC cells, and n=3 knock-out NSC cells. The cell lines originate from
three animals.
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5.2.5 Cell Treatment with Chemically altered EZH2 Inhibitors
The EZH2 inhibitor GSK126 does not cross the blood-brain-barrier thus in
theory neural stem cells could react to a possible treatment. Therefor, neu-
ral stem cells were incubated with the EZH2 inhibitor, and the H3K27me3
protein level was analyzed.
To maybe overcome the blood-brain-barrier in the future the inhibitor
was chemically altered (by Dr. Aubry Miller) to enable an efficient crossing.
The different versions of this inhibitor were first tested on HEK293T cells to
determines the working concentration, and then tested on neural stem cells
to check whether the chemical alteration had an influence on the inhibitor
function.
Different concentrations of the EZH2 inhibitor were tested, and showed
a downregulation of H3K27me3 already with a concentration of 100 nM in
comparison to the Control cells with no treatment, while BDNF and EZH2
protein level remained unchanged (Fig. 53A). Further, different versions
of the EZH2 inhibitor were tested on neural stem cells. Since 3 and 10
mM gave good results, these concentrations were further used. After 72h
of incubation with the different EZH2 inhibitors and chemical altered
versions, the neural stem cells were harvested and 20 µl protein per sample
was blotted for EZH2, beta-tubulin and H3K27me3. A reduced H3K27me3
signal for the inhibitor-treated cells could be observed, in comparison to
the Control cells treated with DMSO (Fig. 53B)25.
5.2.6 BrdU Distribution in the Dentate Gyrus - non significant Data
A single knock out of EZH2 was analyzed by Yuting Li and the preliminary
data hinted toward a different distribution of DCX positive cells in the
dentate gyrus.
Therefore, ten week oly mice of the double knock out
(NesCreERT2;CHD7fl/fl;EZH2fl/fl) and Control litter mates were an-
alyzed according to their cell distribution of BrdU positive cells in regions
of the dentate gyrus.
First, dentate gyrus sizes were compared by using a volume measure-
ment tool (ImageJ) and the BrdU positive cells were counted manually.
To count the cells per region, the dentate gyrus was separated into three
regions of the same width using a line drawing tool (ImageJ). The positive
cells were counted in a blind analysis of knock out and Control animals.
The distribution of BrdU positive cells in the subgranular zone (SGZ), the
25Beyond the scope of this project these chemically altered inhibitors were further tested
on blood-brain-barrier models
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Figure 53: Chemical altered EZH2 inhibitors are still capable of
H3K27me3 downregulation in neural stem cells A: HEK293T cells were
incubated with a chemical variation of the EZH2 inhibitor GSK126 (64) with
the concentration of 30 nM, 100 nM, 300 nM, 1 mM, 3 mM, and 10 mM. The
cells were treated for 72h, then harvested and 20 µl protein per sample was
blotted for EZH2, beta-tubulin, BDNF and H3K27me3. B: Neural stem cells
were treated a chemical variation of the EZH2 inhibitor GSK126 (460, 459,
458) with the concentration of 3 mM, and 10 mM. The cells were treated for
72 h, then harvested and 20 µl protein per sample was blotted for EZH2,
beta-tubulin, BDNF and H3K27me3.
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Figure 54: Neural stem cells treated with GSK2, GSK5, EPZ2, EPZ5,
DMSO. DMSO and the chemical GSK126 variation 464 The cells were
treated for 72 h, then harvested and 20 µl protein per sample was blotted
for EZH2, beta-tubulin, BDNF and H3K27me3.
Figure 55: Neural stem cells treated with chemical GSK126 variation 463
to 458, DMSO, GSK5 and EPZ5 The cells were treated for 72 h, then har-
vested and 20 µl protein per sample was blotted for EZH2, beta-tubulin,
BDNF and H3K27me3.
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Figure 56: Neural stem cells treated with chemical GSK126 variation 454,
453, 453, 457, 456, 455. DMSO, GSK5 and EPZ5 are Controls The cells were
treated for 72 h, then harvested and 20 µl protein per sample was blotted
for EZH2, beta-tubulin, BDNF and H3K27me3.
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middle and upper granular layer (GL) were counted.
The only observed difference concerned running and non running
animals. No significant differnce has been observed between the mutant
and Control group (Fig. 57).
5.2.7 DCX in the Dentate Gyrus - non significant Data
Dentate gyrus sizes were compared by using a volume measurement. DCX
positive cells were counted manually (Fig.58, 2).
To count the cells per region, the dentate gyrus was separated into
three regions of the same width using a line drawing tool (ImageJ). After
a blind analysis the distribution of doublecortin positive cells in the
subgranular zone (SGZ), the middle and upper granular layer (GL) were
not significantly different between the mutant and Control group (Fig. 58,
3).
In the single knock-out of EZH2, Yuting Li saw that the neurons
develop more processes than their Control litter mates. This has not been
observed in the double knock-out. The length of the primary process was
analyzed (Fig. 59, 1).
Only the knock-out mouse group that was sacrificed two weeks after
the tamoxifen injection had significantly shorter primary processes (Fig.
59, 2).
To answer the question whether the neurons of the double knock-out
are bigger or shorter than the Control neurons, the longest visible neuronal
branch was measured using a tool. Seventy cells of Control mice and 40
cells of mutant mice dentate gyrus were measured and compared. There
was no significant difference between the neuronal length of the mutant
and the Control mice group (Fig. 58, 3).
To exclude that only neurons of a certain length were considered all
measured dendritic lengths of 70 Control and 40 knock-out neurons were
plotted together. The distribution lays in between 100 and 300 µm, Control
and knock-out neurons are quite equal distributed (Fig. 58, 4).
During the blind analysis of the doublecortin stainings some of the
cells were attracting attention. Against the normal direction of growth
their primary processes were growing in a ninety degree angle left or right
into the granular layer (Fig. 60, 1).
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Figure 57: Immunofluorescence picture and regional cell num-
ber quantification of BrdU positive cells in the dentate gyrus
(NesCreERT2;CHD7fl/fl;EZH2fl/fl) The ten week old litter mates were
treated with Tamoxifen for 5 days and after another two weeks BrdU was
injected and the mice were placed into a running cage. Subsequently 40µm
brain vibratom slices of the dentate gyrus were stained with Doublecortin
(santa cruz, goat 1:100). The quantification was done manually and 4 to
6 dentate gyrus pictures were count per animal. Control n=5, double KO
n=6, Control runner n=5,double KO runner n=7.Before counting the den-
tate gyrus was separated into subgranular zone (SGZ), middle and upper
granular layer (GL), cells were counted per region.
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Figure 58: Histology picture and regional cell number quan-
tification of Doublecortin positive cells in the dentate gyrus
(NesCreERT2;CHD7fl/fl;EZH2fl/fl). 1: The ten week old litter mates
were treated with Tamoxifen for 5 days and after another two weeks and
the mice were placed into a running cage. Brain slices were stained with
Doublecortin. 2: Control of the dentate gyrus size. The dentate gyrus was
measured entirely with a polygon tool of the microscope software and
compared between mutant and Control. 3: The quantification was done
manually and 4 to 6 dentate gyrus pictures were count per animal. Before
counting the dentate gyrus was separated into subgranular zone (SGZ),
middle and upper granular layer (GL), cells were counted per region; n= 5
mutant and n=6 Control mice.
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Figure 59: Histology picture and quantifications of the cell pro-
cess length for Doublecortin positive cells in the dentate gyrus
(NesCreERT2;CHD7fl/fl;EZH2fl/fl). 1: The ten week old litter mates were
treated with Tamoxifen for 5 days and after another two weeks and the
mice were placed into a running cage. Brain slices were stained with Dou-
blecortin. Example pictures show the measured length of the primary pro-
cesses and the visible dendritic length. 2 and 3: The quantification was
done with a measuring tool of the microscope software, 4 to 6 dentate gyrus
pictures per animal were screened. N-values stand for animals per time
point and genotype. 2: Used were only primary processes where the first
branching was visible. 3: Only the longest visible continuous dendrites
were measured. 4: Graph of the over all distribution of all considered
dendrite length, only separated into Control and mutant group. Statisti-
cal analysis t-test p=0.046.
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(The used animals and staining procedure were the same as mentioned
for Fig. 32). All wrong orientated cells in the subgranular zone (SGZ) were
counted and plotted for the Control and the mutant mouse group. They
were not significantly different (Fig. 60, 2).
For the hillus region these cells were counted too and did not show a
difference in the groups (Fig. 60, 3).
In the following it was analyzed whether cells without visible process
occur more often in the subgranular zone (SGZ) of knock-out mice as
this could be a hint towards not integrated cells. (The used animals and
staining procedure were the same as mentioned in Fig. 32).
For seven animals four to six dentate gyrus were counted for these cells
but no significant difference was found Fig. 60, 2.
5.2.8 NestinCre Survival Study
As the homozygous knock-out of both CHD7 and EZH2 is lethal, the
knock-out was combined with a Nestin promotor to limit the knock-out
to brain stem cells. From the time point nestin is expressed the knock-out
is active and therefore influencing the embryonic development. With this
genetic system (NesCre;CHD7fl/fl) Weijun could show that a homozygous
knock-out is already seldom with 4% of the total number of born pups and
interestingly all surviving animals were female (W. Feng unpublished).
To analyze whether a reduces EZH2 expression could increase the
survival of NesCre;CHD7fl/fl mice we used a mating strategy giving
us the variety of genetic combinations restricted to neural stem cells
(namely NesCre;CHD7fl/fl;EZH2fl/fl, NesCreCHD7+/fl;EZH2+/fl,
NesCre;CHD7fl/fl;EZH2+/fl, NesCre;CHD7fl/fl;EZH2+/fl).
The double homozygous combination of CHD7 and EZH2 was lethal,
the pups seemed fully developed but were born dead. A combination
of CHD7 homozygous and EZH2 heterozygous survived birth, but died
shortly after. Interestingly, a heterozygous expression of CHD7 could pro-
long the survival of a homozygous EZH2 knock-out. Instead of 12 days for
a homozygous EZH2 knock-out, these pups survived 3 weeks. They were
severely underfeed and died with their eyes still closed. Further remark-
able seems that a double heterozygous combination of CHD7 and EZH2
equalizing CHARGE and Weaver syndrome together in the neural stem
cells, was indistinguishable from the Control mice. All of these double
heterozygous mice were killed with 10 weeks of age and showed no ab-
normalities. All these observations were made together with Weijun Feng
(Fig. 62).
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Figure 60: Histology picture and quantification of disori-
entated Doublecortin positive cells in the dentate gyrus
(NesCreERT2;CHD7fl/fl;EZH2fl/fl). 1. The ten week old litter mates were
treated with Tamoxifen for 5 days and after another two weeks and the
mice were placed into a running cage. Subsequently 40µm brain vibratom
slices of the dentate gyrus were stained with Doublecortin. Only cells
with a clear left or right orientation agains the hillus-granular layer axis
were considered. The quantification was done manually and 4 to 6 dentate
gyrus pictures were count per animal. For each group Control (cre-) and
mutant (cre+) n=7. 2: Number of cells with a wrong orientation in the
granular layer. 3: Number of cells with a wrong orientation in the hillus.
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Figure 61: Histology picture and quantification Doublecortin positive
cells in the dentate gyrus (NesCreERT2;CHD7fl/fl;EZH2fl/fl). 1: The ten
week old litter mates were treated with Tamoxifen for 5 days and after an-
other two weeks and the mice were placed into a running cage. Subse-
quently 40µm brain vibratom slices of the dentate gyrus were stained with
Doublecortin. The quantification was done manually and 4 to 6 dentate
gyrus pictures were count per animal. 2: Number of cells without visible
dendrite in the subgranular layer (SGL).
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Figure 62: The survival days of different knock-out combinations (Ne-
sCre;CHD7flox;EZH2flox) A double heterozygous combination was indis-
tinguishable from the Control litter mates. These mice were sacrificed 70
days after birth.
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Figure 63: Complete western blot for
H3K27me3 (17 kDa) using the harvested
HEK293T cells with chd7 knock-down after 48h
and 72 h of GSK126 incubation.
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